0% found this document useful (0 votes)

424 views79 pages

2.21 - ZA - eCTD - Module - 1 - Technical - Sept 16 - v2.1

This document provides requirements for submitting applications for medicine registration in South Africa using the electronic Common Technical Document (eCTD) format, outlining the file formats, signatures, links and handling of empty sections for Module 1 submissions. Guidelines and forms are available from the office of the Registrar of Medicines and on their website to help applicants adhere to the administrative requirements and avoid delays in application processing and evaluation. The document also details the general architecture including the envelope, directory structure, file naming conventions and change control process for South African eCTD Module 1 submissions.

Uploaded by

vinay

We take content rights seriously. If you suspect this is your content, claim it here.

Available Formats

Download as PDF, TXT or read online on Scribd

0% found this document useful (0 votes)

424 views79 pages

2.21 - ZA - eCTD - Module - 1 - Technical - Sept 16 - v2.1

Uploaded by

vinay

We take content rights seriously. If you suspect this is your content, claim it here.

Available Formats

Download as PDF, TXT or read online on Scribd

You are on page 1/ 79

Registration of Medicines ZA eCTD Module 1 Technical Specification

MEDICINES CONTROL COUNCIL

South African Specification for eCTD Regional -

Module1

This document is intended to provide requirements to applicants wishing to submit applications for the registration of medicines
in eCTD format. It reflects the current situation and will be regularly updated with change in legislation and experience gained. It
is important that applicants adhere to the administrative requirements to avoid delays in the processing and evaluation of
applications.
Guidelines and forms are available from the office of the Registrar of Medicines and the website.

First publication released for pilot implementation and comment March 2013

Version 2 October 2016

Version 2.1 November 2016

Implementation 01 May 2017

DR JC GOUWS
REGISTRAR OF MEDICINES

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 1 of 79

Registration of Medicines ZA eCTD Module 1 Technical Specification

TABLE OF CONTENTS

LIST OF TABLES ............................................................................................................................................... 3

ABBREVIATIONS AND ACRONYMS ................................................................................................................ 4

DEFINITIONS ..................................................................................................................................................... 5

1 INTRODUCTION ...................................................................................................................................... 6
1.1 Background ............................................................................................................................................ 6
1.2 Scope ..................................................................................................................................................... 6
1.3 Technical Requirements ......................................................................................................................... 6

2 SOUTH AFRICAN REGION SPECIFIC INFORMATION: MODULE 1 .................................................... 7

3 SOUTH AFRICAN FILE FORMATS ......................................................................................................... 7

3.1 Module 1 ................................................................................................................................................. 7
3.2 Modules 2 to 5 ........................................................................................................................................ 8

4 USE OF ELECTRONIC SIGNATURES ................................................................................................... 8

5 LINKS (PDF Hyperlinks) ........................................................................................................................... 8

6 HANDLING OF EMPTY OR MISSING eCTD SECTIONS ....................................................................... 8

7 GENERAL ARCHITECTURE OF MODULE 1 ......................................................................................... 8

7.1 za-envelope ............................................................................................................................................ 9
7.2 m1-za ...................................................................................................................................................... 9
7.3 Directory / File Structure ....................................................................................................................... 10
7.4 Node Extensions .................................................................................................................................. 10
7.5 File Naming Convention ....................................................................................................................... 10
7.6 Folder and Filename Path Length ........................................................................................................ 10

8 CHANGE CONTROL.............................................................................................................................. 11

9 UPDATE HISTORY ................................................................................................................................ 11

Appendix 1: Directory / File Structure for ZA Module 1 .................................................................................... 12

Appendix 2: Envelope Element Description ..................................................................................................... 41

Appendix 3: Example Screenshots ................................................................................................................... 47

Appendix 4: Creating the XML ZA Submission ................................................................................................ 50

Appendix 5: Modularised DTD for ZA Module 1 ............................................................................................... 51

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 2 of 79

Registration of Medicines ZA eCTD Module 1 Technical Specification

LIST OF TABLES

Table 1: Acceptable file formats for ZA Module1 .................................................................................................7

Table 2: Overview on the content of ZA Module 1 ............................................................................................ 12

Table 3: Directory / file structure ........................................................................................................................ 15

Table 4: Conventions ......................................................................................................................................... 15

Table 5: Directory / file structure for ZA Module 1 ............................................................................................. 16

Table 6: Example of how the Related Sequence should be used ..................................................................... 45

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 3 of 79

Registration of Medicines ZA eCTD Module 1 Technical Specification

ABBREVIATIONS AND ACRONYMS

API Active Pharmaceutical Ingredient
Applicant The Proposed / Holder of Certificate of Registration
BE Bioequivalence
BMR Batch manufacturing record
CEP Certificate of Suitability (Ph Eur monograph)
CoA Certificate of Analysis
CPP Certificate of Pharmaceutical Product
CTD Common Technical Document
DTD Document Type Definition
eCTD electronic Common Technical Document
EMA European Medicines Agency
EWG Expert Working Group
GCP Good Clinical Practice
GMO Genetically Modified Organism
GMP Good Manufacturing Practice
HCR Holder of Certificate of Registration
ICH International Council for Harmonisation (of Technical Requirements for Registration of
Pharmaceuticals for Human Use)
INN International Non-proprietary Name
IPI Inactive Pharmaceutical Ingredient
IT Information technology
MCC Medicines Control Council
NCE New Chemical Entity
OCR Optical Character Recognition
PDF Portable Document Format
P&A Pharmaceutical and Analytical
PHCR Proposed Holder of Certificate of Registration
PI Package Insert
PIL Patient Information Leaflet
PMF Plasma Master File
VAMF Vaccine Antigen Master File
WHO World Health Organisation
XML Extensible Markup Language
ZA/SA South Africa

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 4 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

DEFINITIONS

Application number: The application number is the official reference number assigned to the dossier or
eCTD application by the MCC. It remains with the dossier for its full life cycle and
also in archiving.

Dossier: A collection of documents compiled by an applicant/PHCR in compliance with South

African legislation and guidelines in order to seek registration of a medicine, or any
amendments thereof. An application may comprise a number of submissions.

eCTD application: A collection of electronic documents compiled by an applicant/PHCR in compliance

with South African legislation and guidelines in order to seek registration of a
medicine, or any amendments thereof. An eCTD application may comprise a
number of eCTD Sequences. In South Africa an eCTD application may comprise
several strengths, each with a unique proprietary name. Such a collection may also
be described as a dossier.

eCTD identifier: An eCTD identifier is the application number used as the directory name in the top-
level directory.

eCTD Sequence: All files and folders in a submission in eCTD format are to be placed under the
eCTD-Sequence number folder (equivalent to the term "sequence" used by the
EMA)

eCTD Submission: An eCTD Submission is an electronic-only submission in the eCTD format that is
supported by paper documents (e.g. some documents from Module 1).

Regulatory activity: A regulatory activity is a logical entity of submission activity (for example a new
indication) with a defined start and end point (e.g. initial submission to final
approval). In the eCTD world, a regulatory activity consists of all the eCTD
Sequences that together make up the lifecycle of that particular regulatory activity.

It can also be defined as a collection of sequences covering the start to the end of a
specific business process, e.g. an initial application for registration or a type C
amendment. It is a concept used to group together several business related
sequences.

Submission / Sequence: A single set of information and/or documents supplied by the applicant/PHCR as a
partial or complete application. In the context of eCTD, this is equivalent to ‘eCTD
Sequence’.

Submission Type: The submission type describes the type of regulatory submission / type of procedure
that the content relates to.

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 5 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

1 INTRODUCTION
This document specifies Module 1 of the electronic Common Technical Document (eCTD) for South
Africa (“ZA”).
eCTD is the only valid format for electronic-only submissions to the South African Regulatory Authority.
The document should be read in conjunction with the ICH eCTD Specification to prepare a valid eCTD
submission for South Africa. The latest version of the ICH eCTD Specification can be found at:
http://estri.ich.org/ectd.
The eCTD is defined as an interface for industry to agency transfer of regulatory information while at the
same time taking into consideration the facilitation of the creation, review, life cycle management and
archiving of the electronic submission.
The eCTD specification lists the criteria that will make an electronic submission technically valid. The
focus of the specification is to provide the ability to transfer the registration application electronically
from industry to a regulatory authority.
Industry to industry and authority to authority transfer is not addressed.

1.1 Background
The specification for the eCTD is based upon content defined within the CTD issued by the ICH M4
EWG. The CTD describes the organisation of modules, sections and documents. The structure and
level of detail specified in the CTD have been used as the basis for defining the eCTD structure and
content but, where appropriate, additional details have been developed within the eCTD specification.
The philosophy of the eCTD is to use open standards. Open standards, including proprietary
standards which through their widespread use can be considered de facto standards, are deemed to
be appropriate in general.

1.2 Scope
The CTD as defined by the M4 EWG does not cover the full submission that is to be made in a region.
It describes only modules 2 to 5, which are common across all regions. The ICH CTD specifies that
Module 1 should contain region-specific administrative and product information. The CTD does not
describe the content of module 1 because it is regional specific, nor does it describe documents that
can be submitted as amendments or variations to the initial application.
The value of producing a specification for the creation of an electronic submission based only upon
the modules described in the CTD would be limited. Therefore, the M2 EWG has produced a
specification for the eCTD that is applicable to all modules of initial registration applications and for
other submissions of information throughout the life cycle of the product, such as variations and
amendments.

1.3 Technical Requirements

The specification is designed to support high-level functional requirements such as the following:
• Copying and pasting
• Viewing and printing of documents
• Annotation of documentation
• Facilitating the exporting of information to databases
• Searching within and across applications
• Navigating throughout the eCTD and its subsequent amendments/variations

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 6 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

2 SOUTH AFRICAN REGION SPECIFIC INFORMATION: MODULE 1

The ICH Common Technical Document (“CTD”) specifies that Module 1 should contain region-specific
administrative and product information.
Depending on the type of application, region-specific administrative and product information has to be
provided in Module 1.
Appendix 1 gives a detailed overview on all the possible documents in Module 1. Depending on the
type of application, the phase of the application (e.g. initial submission, responses to recommendations)
and the type of product (e.g. oral galenic form, vaccine) not all elements are to be provided. The
current practice has to be taken into account. The table includes all submission types although some of
them may only become suitable for eCTD submission at a later stage. Please refer to the Guidance for
the submission of Regulatory Information in eCTD Format.
A Letter of Application, Application Form(s) (one per strength), and a Validation Template are
mandatory.
This document describes only the region-specific information that is common to all eCTD submissions
in South Africa.

3 SOUTH AFRICAN FILE FORMATS

3.1 Module 1
The file formats that can be included in Module 1 are given in Table 1. PDF, as defined by the ICH
eCTD Specification, is the only format acceptable – see table.
South African labelling and packaging documents in Module1.3, in the proprietary format MS Word
should not be referenced in the eCTD backbone and should always be provided in addition to the PDF
versions.
Note that all PDF files included in an eCTD (irrespective of the module) should be in the format PDF
1.4, 1.5, 1.6 or 1.7.

Table 1: Acceptable file formats for ZA Module1

Document File Format Remark

Letter of Application PDF A scan of the originally signed document is mandatory.
The file must be searchable (OCR scanned)

Application Form PDF A scan of the originally signed document is mandatory.

The file must be searchable (OCR scanned)
ZA labelling and packaging: PI, PDF Include working documents as MS Word (please refer to
1
PIL and label PDF the respective section in the guidance document 2.23)
in addition to the PDF for the PI, PIL and label, for ease
of review, in addition to the eCTD submission.*
Other PDF PDF preferably generated from electronic source.
*For the correct naming of the files please refer to the Guidance document
In addition, the PDF files should follow the general ICH requirements of Modules 2 to 5 regarding size
limitations, security settings/password protection etc. Files, folders or submissions should not be
zipped.

1
2.23 Guidance for the submission of regulatory information in eCTD format

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 7 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

3.2 Modules 2 to 5
No additional file formats are defined for Modules 2 to 5 other than those mentioned in the ICH eCTD
Specification Document.
The ICH DTD definition (and the files) remain unchanged. A detailed use of Section 3.2.R is given in
the Guidance for the submission of regulatory information in eCTD format.

4 USE OF ELECTRONIC SIGNATURES

The use of advanced electronic signatures (digital signatures) will be crucial in achieving pure electronic
communication between the pharmaceutical industry and regulatory agencies, particularly for
authentication of electronic submissions and documents contained therein. South Africa will therefore
be developing a long-term strategy to implement digital signatures. Currently however, the use of
digital signatures for electronic submissions within South Africa is not fully supported and digital
signatures should therefore not be used.
Scanned signatures in the electronic Module 1 are allowed since paper copies of certain documents of
Module 1 including the original signed versions of the forms and the Letter of Application are required
(please refer to the Guidance for the submission of Regulatory Information in eCTD Format for further
details).
Module 1.2.2.4 should include an attestation that the paper and electronic versions of the submission,
the South African labelling and packaging and the Letter of Application are identical.

5 LINKS (PDF Hyperlinks)

Links among objects in the eCTD submission should be relative. The intention is to make the eCTD
submission self-contained.
Links among objects in Module 1 are allowed.
Hyperlinks from Module 1 to other modules are allowed.

6 HANDLING OF EMPTY OR MISSING eCTD SECTIONS

For new applications (including generic applications), detailed statements justifying the absence of data
or specific eCTD sections should be provided in the relevant Quality Overall Summary and/or Non-
Clinical/Clinical Overviews (Module 2.3, 2.4, 2.5). If relevant, justification for absence of data or empty
sections in Module 1 is to be provided in the Letter of Application.
Note that placeholder documents highlighting 'no relevant content' should not be placed in the eCTD
structure, as these would create a document lifecycle for non-existent documents, and unnecessary
complication and maintenance of the eCTD.

7 GENERAL ARCHITECTURE OF MODULE 1

The ZA Module 1 architecture is similar to that of Modules 2 to 5 of the eCTD, comprising a directory
structure and a backbone with leaves. The backbone must be a valid XML document according to the
ZA Regional Document Type Definition (DTD).
The backbone (the za-regional.xml file) contains metadata for the leaves, including pointers to the files
in the directory structure.
In addition, the South African Regional DTD defines metadata at the submission level in the form of an
envelope. The root element is “za-backbone” and contains two elements: “za-envelope” and “m1-za”.

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 8 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

The ZA Regional DTD is modularised i.e. the envelope and leaves are referenced from the main part of
the DTD as external entities called respectively "za-envelope.mod" and "za-leaf.mod ". The ZA ”leaf” is
identical to the leaf element described in the ICH eCTD DTD; refer to Table 6-8 of the ICH eCTD
Specification.
A full description of the ZA Regional DTD can be found in Appendix 5 of this specification.
Examples of the directory structure for any application are given in Appendix 3 of this specification. The
leaves need to be equipped with information according to the requirements for a given type of
submission.
Note that files can be referenced across modules i.e. content files in Modules 2 to 5 (in the index.xml)
can be referred to from the za-regional.xml (Module 1) and vice versa.
The eCTD contains more than documents and requires the applicant to deliver technical information
such as the DTD, the MD5 checksum, additional metadata, and other information. A list of files that are
required by the South African Regulatory Authority in addition to the documents is as follows:
Sequence number folder:
• index.xml: eCTD backbone file, the table of content
• index-md5.txt the MD5 checksum file
Util folder:
• dtd folder File folder for document type definition files
• style folder File folder for style sheet

DTD folder:
• za-envelope.mod
• za-leaf.mod
• za-regional.dtd ZA regional DTD
• ich-ectd-3-2.dtd ICH DTD

Style folder:
• za-regional.xsl ZA regional style sheet file
• ectd-2-0.xsl ICH style sheet file
Other file formats such as .doc may be required in addition to the PDF requirement of the eCTD. These
files should not be added as leaf elements (documents) within the eCTD structure. They should be
provided in a separate folder called “<eCTD sequence>-workingdocuments” (e.g. 0000-
workingdocuments), on the CD/DVD containing the eCTD. Please refer to the Guidance for the
submission of Regulatory Information in eCTD Format for guidance on the structure of this folder.

7.1 za-envelope
The “za-envelope” element is designed to be used for all types of submissions (new products,
amendments, responses, etc.) for a given medicinal product and will be required for each submission.
The envelope provides metadata at the submission level.
A description of each "envelope" element is provided in Appendix 2 of this specification.

7.2 m1-za
The “m1-za” element of the ZA regional DTD is based on the same conceptual approach as the
common part of the ICH eCTD DTD. It provides an XML catalogue with metadata at the leaf level
including pointers to the location of files in a directory structure. As for the ICH eCTD DTD, the “m1-
za” element maps to the directory structure. (There may at times be what is seen to be a 'redundant'
directory structure, but this is necessary in order to be able to use the same file / directory structure for
all procedures.)

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 9 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

7.3 Directory / File Structure

The ZA Module 1 Specification provides the directory and file structure, see Appendix 1.

7.4 Node Extensions

Node extensions are a way of providing extra organisational information to the CTD. The node
extension should be visualised as an extra heading in the CTD structure. The following rules apply to
node extensions in ZA eCTDs:
• Node extensions must not be used where ICH-specified sub-headings already exist (e.g.
indication, manufacturer, drug substance, drug product are all-ICH specified node extensions).
• Node extensions must only be used at the lowest level of the eCTD structure (for example a node
extension can be used at the level 5.3.5.1 but must not be used at the level 5.3).
• Node extensions are mainly to be used to group together documents made up of multiple leaf
elements (e.g. a clinical study made up of separate files for the synopsis, main body and individual
appendices could be grouped together under a node extension with the Study Identifier as its Title
attribute).
• Node extensions must be maintained over the entire life of the eCTD lifecycle (for example if a
node extension is used in eCTD Sequence 0000 to group files for a study report in Module 5.3.5.1,
then any files submitted in a later eCTD Sequence must also be placed under a node extension,
even if only one file is submitted).
• Node extensions may be nested as this is allowed by the eCTD DTD. However, as noted in
bullet 2, the first node extension must be at the lowest level in the eCTD structure (e.g. in Module
5.3. a node extension may be added to group together files with the Study Identifier as Title
attribute). Further node extensions may be added as children of the Study Identifier node,
separating CRFs from individual patient listings.

7.5 File Naming Convention

File names have fixed and variable components. Components are separated by a hyphen.
Fixed components are highly recommended. The variable component is optional and should be used
as appropriate to further define these files. The variable component, if used, should be a meaningful
concatenation of words without separation and should be kept as brief and descriptive as possible.
File extensions in line with this specification should be applied as applicable.
The first component should be the fixed component of the filename, as per Appendix 1, Table 1.
The second component if necessary should be the variable component. In cases where differentiation
is needed (e.g. between 1,5 mg and 15 mg), it is suggested that the word 'point' is written in full i.e.
‘1point5mg’.
There are no recommendations for variable components in this specification. The format of the file is
indicated by the file extension.
File names should always be in lowercase, in line with the ICH eCTD specification. Examples are:
• application-letter-10mg.pdf
• label-10mg.pdf

7.6 Folder and Filename Path Length

The overall folder and filename path length starting from the sequence number should not exceed
180 characters for any file in any module.

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 10 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

8 CHANGE CONTROL
The ZA Module 1 specification is likely to change with time. Factors that could affect the content of the
specification include, but are not limited to:
• Change in the content of the Module 1 for the CTD/eCTD, either through the amendment of
information, at the same level of detail, or by provision of more detailed definition of content and
structure
• Inclusion of new application types initially not included in the eCTD set
• Change to the regional requirements for applications that are outside the scope of the CTD
• Update of standards that are already in use within the eCTD
• Identification of new standards that provide additional value for the creation and/or usage of the
eCTD
• Identification of new functional requirements
• Experience of use of the eCTD by all parties, in particular Module 1.

9 UPDATE HISTORY

Date Reason for update Version & publication

Feb 2013 First publication as working document v1_23 working document
Feb 2013
March 2013 Publication for implementation of pilot phase and comment v1 March 2013
Sept 2016 Amendment of sections Abbreviations & Acronyms, v2 October 2016
Definitions, 2, 3.1, 4, Appendix 1, Appendix 2 (Table 5),
Appendix 3, Appendix 4
Added section 7.6
Sept 2016 Correction of DTD, editorial changes v2.1 November 2016
01 May 2017 Implementation

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 11 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Appendix 1: Directory / File Structure for ZA Module 1

Table 2 gives an overview on the contents of Module 1. The current practice has to be taken into account to
define which documents are needed according to the submission types, and the documents listed below
should be provided where applicable. Please refer to the current guidelines and the Guidance for the
submission of regulatory information in eCTD format to identify which documents need to be included in the
submission.
File names have fixed and variable components. Components are separated by a hyphen. No hyphens or
spaces should be used within individual components. The fixed components are defined in the table below. A
filename is composed as follows: fixedcomponent-variablecomponent.ext (see also table 3). For each leaf
described below, node extensions are allowed.

Table 2: Overview on the content of ZA Module 1

No Title Fixed Component of

File Name
1.0 Letter of Application application-letter
1.2 Application
1.2.1 Application Form application-form
1.2.2 Annexes
1.2.2.1 Proof of Payment proof-of-payment
1.2.2.2 Letter of Authorisation letter-of-authorisation
1.2.2.3 Dossier Product Batch Information dossier-product-batch-
information
1.2.2.4 Electronic Copy Declaration electronic-copy-
declaration
1.2.2.5 Curriculum Vitae of the person responsible for pharmacovigilance cv-pharmacovigilance
1.2.2.6 API change control api-change-control
1.2.2.7 EMA certificate for a Vaccine Antigen Master File (VAMF) vamf-certificate
1.2.2.8 EMA certificate for a Plasma Master File (PMF) pmf-certificate
1.3 South African labelling and packaging
1.3.1 South African Package Insert
1.3.1.1 Package Insert pi
1.3.1.2 Standard References stdrefs
1.3.2 Patient Information Leaflet pil
1.3.3 Labels label
1.3.4 Braille braille
1.4 Information about the experts
1.4.1 Quality quality
1.4.2 Non-clinical non-clinical
1.4.3 Clinical clinical

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 12 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

No Title Fixed Component of

File Name
1.5 Specific requirements for different types of applications
1.5.1 Literature based submissions literature-based
1.5.2 Amendments/Variations
1.5.2.1 Tabulated Schedule of Amendments amendment-schedule
1.5.2.2 Medicines Register Details medicine-register
1.5.2.3 Affidavit by Responsible Pharmacist affidavit
1.5.3 Proprietary name applications and changes proprietary-name
1.5.4 Genetically Modified Organisms gmo
1.5.5 PI and PIL amendments/updates pi-amendment
1.6 Environmental Risk Assessment
1.6.1 Non-GMO (Genetically Modified Organisms) nongmo
1.6.2 GMO (Genetically Modified Organisms) gmo
1.7 Good Manufacturing Practice
1.7.1 Date of last inspection of each site last-inspection
1.7.2 Inspection reports or equivalent document inspection-report
1.7.3 Latest GMP certificate or a copy of the appropriate licence gmp-certificate
1.7.4 Release
1.7.4.1 API api
1.7.4.2 IPIs ipi
1.7.4.3 Finished Product Release Control (FPRC) tests fprc-tests
1.7.4.4 Finished Product Release Responsibility (FPRR) criteria fprr-criteria
1.7.5 Confirmation of contract contract-confirmation
1.7.6 CPP (WHO certification scheme) cpp
1.7.7 SAPC registration sapc-reg
1.7.8 Registration with Registrar of Companies comp-reg
1.7.9 Other documents relating to the Applicant/PHCR phcr
1.7.10 Sample and Documents
1.7.10.1 Confirmation of submission of sample confirmation-sample
1.7.10.2 Batch manufacturing record of the sample sample-bmr
1.7.10.3 CoA of the sample sample-coa
1.7.11 Certified copy of a permit to manufacture specified Schedule 5, manufacturing-permit
Schedules 6, 7 and 8 substances
1.7.12 Inspection flow diagram inspection-flow-diagram
1.7.13 Organogram organogram
1.8 Details of compliance with screening outcomes compliance-screening
1.9 Individual patient data - statement of availability indiv-patient-data

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 13 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

No Title Fixed Component of

File Name
1.10 Foreign regulatory status
1.10.1 List of countries in which an application for the same product as countries-same-appl
being applied for has been submitted
1.10.2 Registration certificate or marketing authorisation foreign-reg-cert-or-ma
1.10.3 Foreign prescribing and patient information foreign-pi
1.10.4 Data set similarities data-set-similarities
1.11 Bioequivalence trial information be-trial-info
1.12 Paediatric development programme paediatric-dev-program
1.13 Risk management plan risk-management-plan

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 14 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
The directory / file structure is defined in this appendix as a table containing the following information:

Table 3: Directory / file structure

Sequential number Each item in the table has a unique sequentially assigned reference number. These reference numbers can
change with each version of this appendix.
Number CTD section number
Title CTD title
Element Element name in the ZA Backbone
File/Directory File/Directory name from m1/za – should be relative path from za/m1 e.g. m1-0-application-letter/application-
letter.pdf.
This is consistent with ICH standards. The file extension corresponds to the file type; i.e. the “pdf” extension
is only illustrative.
Comment Comments

The following conventions are used:

Table 4: Conventions

Codes Definition
FIXED Fixed component of the filename (see table 1)
VAR * Variable component of the filename
EXT File extension, usually pdf
DDDD An eCTD Sequence number made of 4 digits (e.g. 0000)

The names of the actual files and directories used should be presented in lower case in accordance with the eCTD specification. The use of upper case
for those codes is for illustrative purposes only to show differentiation between the variable parts and the fixed part of the name.
*)The variable component, when used, should be a logical name and preceded by a hyphen. The variable component itself must follow the current ICH
eCTD naming convention (e.g. can contain a hyphen but no spaces e.g. 10mg.pdf). When only one component is submitted in a directory, it is
recommended that there is no variable component in the filename, e.g. when only the letter of application is submitted in the directory, the file name
should be application-letter.pdf.

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 15 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Table 5: Directory / file structure for ZA Module 1

1 Number 1
Title ZA Module 1
Element m1-za
Directory m1/za
Comment Top level directory for the ZA Module 1 as per ICH eCTD Specification
2 Number 1
Title ZA Module 1
Element m1-za
File m1/za/za-regional.xml
Comment The ZA Regional XML instance including the envelope information. Note that the operation attribute for the za-regional.xml should
always be set to ‘new’.
3 Number 1.0
Title Letter of Application
Element m1-0-application-letter
Directory m1/za/10-application-letter
Comment
4 Number 1.0
Title Letter of Application
Element m1-0-application-letter
File m1/za/10-application-letter/application-letter-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 16 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

5 Number 1.2
Title Application
Element m1-2-application
Directory m1/za/12-application
Comment
6 Number 1.2.1
Title Application Form
Element m1-2-1-application-form
Directory m1/za/12-application/121-application-form
Comment
7 Number 1.2.1
Title Application Form
Element m1-2-1-application-form
File m1/za/12-application/121-application-form/application-form-VAR.EXT
Comment
8 Number 1.2.2
Title Annexes
Element m1-2-2-annexes
Directory m1/za/12-application/122-annexes
Comment
9 Number 1.2.2.1
Title Proof of Payment
Element m1-2-2-1-proof-of-payment
Directory m1/za/12-application/122-annexes/1221-proof-of-payment
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 17 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

10 Number 1.2.2.1
Title Proof of Payment
Element m1-2-2-1-proof-of-payment
File m1/za/12-application/122-annexes/1221-proof-of-payment/proof-of-payment-VAR.EXT
Comment
11 Number 1.2.2.2
Title Letter of Authorisation
Element m1-2-2-2-letter-of-authorisation
Directory m1/za/12-application/122-annexes/1222-letter-of-authorisation
Comment Letter of Authorisation for communication on behalf of the applicant/PHCR
12 Number 1.2.2.2
Title Letter of Authorisation
Element m1-2-2-2-letter-of-authorisation
File m1/za/12-application/122-annexes/1222-letter-of-authorisation/letter-of-authorisation-VAR.EXT
Comment
13 Number 1.2.2.3
Title Dossier Product Batch Information
Element m1-2-2-3-dossier-product-batch-information
Directory m1/za/12-application/122-annexes/1223-dossier-product-batch-information
Comment
14 Number 1.2.2.3
Title Dossier Product Batch Information
Element m1-2-2-3-dossier-product-batch-information
File m1/za/12-application/122-annexes/1223-dossier-product-batch-information/dossier-product-batch-information-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 18 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

15 Number 1.2.2.4
Title Electronic Copy Declaration
Element m1-2-2-4-electronic-copy-declaration
Directory m1/za/12-application/122-annexes/1224-electronic-copy-declaration
Comment
16 Number 1.2.2.4
Title Electronic Copy Declaration
Element m1-2-2-4-electronic-copy-declaration
File m1/za/12-application/122-annexes/1224-electronic-copy-declaration/electronic-copy-declaration-VAR.EXT
Comment
17 Number 1.2.2.5
Title Curriculum Vitae of the person responsible for pharmacovigilance
Element m1-2-2-5-cv-pharmacovigilance
Directory m1/za/12-application/122-annexes/1225-cv-pharmacovigilance
Comment
18 Number 1.2.2.5
Title Curriculum Vitae of the person responsible for pharmacovigilance
Element m1-2-2-5-cv-pharmacovigilance
File m1/za/12-application/122-annexes/1225-cv-pharmacovigilance/cv-pharmacovigilance-VAR.EXT
Comment
19 Number 1.2.2.6
Title API change control
Element m1-2-2-6-api-change-control
Directory m1/za/12-application/122-annexes/1226-api-change-control
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 19 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

20 Number 1.2.2.6
Title API change control
Element m1-2-2-6-api-change-control
File m1/za/12-application/122-annexes/1226-api-change-control/api-change-control-VAR.EXT
Comment
21 Number 1.2.2.7
Title EMA certificate for a Vaccine Antigen Master File (VAMF)
Element m1-2-2-7-vamf-certificate
Directory m1/za/12-application/122-annexes/1227-vamf-certificate
Comment
22 Number 1.2.2.7
Title EMA certificate for a Vaccine Antigen Master File (VAMF)
Element m1-2-2-7-vamf-certificate
File m1/za/12-application/122-annexes/1227-vamf-certificate/vamf-certificate-VAR.EXT
Comment
23 Number 1.2.2.8
Title EMA certificate for a Plasma Master File (PMF)
Element m1-2-2-8-pmf-certificate
Directory m1/za/12-application/122-annexes/1228-pmf-certificate
Comment
24 Number 1.2.2.8
Title EMA certificate for a Plasma Master File (PMF)
Element m1-2-2-8-pmf-certificate
File m1/za/12-application/122-annexes/1228-pmf-certificate/pmf-certificate-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 20 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

25 Number 1.3
Title South African labelling and packaging
Element m1-3-za-labelling-packaging
Directory m1/za/13-za-labelling-packaging
Comment
26 Number 1.3.1
Title South African Package Insert
Element m1-3-1-sapi
Directory m1/za/13-za-labelling-packaging/131-sapi
Comment
27 Number 1.3.1.1
Title Package Insert
Element m1-3-1-1-pi
Directory m1/za/13-za-labelling-packaging/131-sapi/1311-pi
Comment
28 Number 1.3.1.1
Title Package Insert
Element m1-3-1-1-pi
File m1/za/13-za-labelling-packaging/131-sapi/1311-pi/pi-VAR.EXT
Comment
29 Number 1.3.1.2
Title Standard References
Element m1-3-1-2-stdrefs
Directory m1/za/13-za-labelling-packaging/131-sapi/1312-stdrefs
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 21 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

30 Number 1.3.1.2
Title Standard References
Element m1-3-1-2-stdrefs
File m1/za/13-za-labelling-packaging/131-sapi/1312-stdrefs/stdrefs-VAR.EXT
Comment
31 Number 1.3.2
Title Patient Information Leaflet
Element m1-3-2-pil
Directory m1/za/13-za-labelling-packaging/132-pil
Comment
32 Number 1.3.2
Title Patient Information Leaflet
Element m1-3-2-pil
File m1/za/13-za-labelling-packaging/132-pil/pil-VAR.EXT
Comment
33 Number 1.3.3
Title Labels
Element m1-3-3-labels
Directory m1/za/13-za-labelling-packaging/133-labels
Comment Mock-ups and specimens of proposed South African labelling OR, if not available, a text only version of the proposed labelling
34 Number 1.3.3
Title Labels
Element m1-3-3-labels
File m1/za/13-za-labelling-packaging/133-labels/label-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 22 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

35 Number 1.3.4
Title Braille
Element m1-3-4-braille
Directory m1/za/13-za-labelling-packaging/134-braille
Comment For future use.
36 Number 1.3.4
Title Braille
Element m1-3-4-braille
File m1/za/13-za-labelling-packaging/134-braille/braille-VAR.EXT
Comment
37 Number 1.4
Title Information about the experts
Element m1-4-expert-information
Directory m1/za/14-expert-information
Comment
38 Number 1.4.1
Title Quality
Element m1-4-1-quality
Directory m1/za/14-expert-information/141-quality
Comment
39 Number 1.4.1
Title Quality
Element m1-4-1-quality
File m1/za/14-expert-information/141-quality/quality-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 23 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

40 Number 1.4.2
Title Non-clinical
Element m1-4-2-non-clinical
Directory m1/za/14-expert-information/142-non-clinical
Comment
41 Number 1.4.2
Title Non-clinical
Element m1-4-2-non-clinical
File m1/za/14-expert-information/142-non-clinical/non-clinical-VAR.EXT
Comment
42 Number 1.4.3
Title Clinical
Element m1-4-3-clinical
Directory m1/za/14-expert-information/143-clinical
Comment
43 Number 1.4.3
Title Clinical
Element m1-4-3-clinical
File m1/za/14-expert-information/143-clinical/clinical-VAR.EXT
Comment
44 Number 1.5
Title Specific requirements for different types of applications
Element m1-5-specific-requirements
Directory m1/za/15-specific-requirements
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 24 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

45 Number 1.5.1
Title Literature based submissions
Element m1-5-1-literature-based
Directory m1/za/15-specific-requirements/151-literature-based
Comment Methodology of literature search, including complete details of any database search strategies
46 Number 1.5.1
Title Literature based submissions
Element m1-5-1-literature-based
File m1/za/15-specific-requirements/151-literature-based/literature-based-VAR.EXT
Comment
47 Number 1.5.2
Title Amendments/Variations
Element m1-5-2-amendment
Directory m1/za/15-specific-requirements/152-amendment
Comment
48 Number 1.5.2.1
Title Tabulated Schedule of Amendments
Element m1-5-2-1-amendment-schedule
Directory m1/za/15-specific-requirements/152-amendment/1521-amendment-schedule
Comment
49 Number 1.5.2.1
Title Tabulated Schedule of Amendments
Element m1-5-2-1-amendment-schedule
File m1/za/15-specific-requirements/152-amendment/1521-amendment-schedule/amendment-schedule-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 25 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

50 Number 1.5.2.2
Title Medicines Register Details
Element m1-5-2-2-medicine-register
Directory m1/za/15-specific-requirements/152-amendment/1522-medicine-register
Comment
51 Number 1.5.2.2
Title Medicines Register Details
Element m1-5-2-2-medicine-register
File m1/za/15-specific-requirements/152-amendment/1522-medicine-register/medicine-register-VAR.EXT
Comment Appendix A1 of Amendments guideline and registration certificate to be included
52 Number 1.5.2.3
Title Affidavit by Responsible Pharmacist
Element m1-5-2-3-affidavit
Directory m1/za/15-specific-requirements/152-amendment/1523-affidavit
Comment
53 Number 1.5.2.3
Title Affidavit by Responsible Pharmacist
Element m1-5-2-3-affidavit
File m1/za/15-specific-requirements/152-amendment/1523-affidavit/affidavit-VAR.EXT
Comment
54 Number 1.5.3
Title Proprietary name applications and changes
Element m1-5-3-proprietary-name
Directory m1/za/15-specific-requirements/153-proprietary-name
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 26 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

55 Number 1.5.3
Title Proprietary name applications and changes
Element m1-5-3-proprietary-name
File m1/za/15-specific-requirements/153-proprietary-name/proprietary-name-VAR.EXT
Comment
56 Number 1.5.4
Title Genetically Modified Organisms
Element m1-5-4-gmo
Directory m1/za/15-specific-requirements/154-gmo
Comment
57 Number 1.5.4
Title Genetically Modified Organisms
Element m1-5-4-gmo
File m1/za/15-specific-requirements/154-gmo/gmo-VAR.EXT
Comment Filename
58 Number 1.5.5
Title PI and PIL amendments/updates
Element m1-5-5-pi-amendment
Directory m1/za/15-specific-requirements/155-pi-amendment
Comment
59 Number 1.5.5
Title PI and PIL amendments/updates
Element m1-5-5-pi-amendment
File m1/za/15-specific-requirements/155-pi-amendment/pi-amendment-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 27 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

60 Number 1.6
Title Environmental Risk Assessment
Element m1-6-environ-risk-assessment
Directory m1/za/16-environ-risk-assessment
Comment
61 Number 1.6.1
Title Non-GMO (Genetically Modified Organisms)
Element m1-6-1-nongmo
Directory m1/za/16-environ-risk-assessment/161-nongmo
Comment
62 Number 1.6.1
Title Non-GMO (Genetically Modified Organisms)
Element m1-6-1-nongmo
File m1/za/16-environ-risk-assessment/161-nongmo/nongmo-VAR.EXT
Comment
63 Number 1.6.2
Title GMO (Genetically Modified Organisms)
Element m1-6-2-gmo
Directory m1/za/16-environ-risk-assessment/162-gmo
Comment
64 Number 1.6.2
Title GMO (Genetically Modified Organisms)
Element m1-6-2-gmo
File m1/za/16-environ-risk-assessment/162-gmo/gmo-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 28 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

65 Number 1.7
Title Good Manufacturing Practice
Element m1-7-gmp
Directory m1/za/17-gmp
Comment
66 Number 1.7.1
Title Date of last inspection of each site
Element m1-7-1-last-inspection
Directory m1/za/17-gmp/171-last-inspection
Comment
67 Number 1.7.1
Title Date of last inspection of each site
Element m1-7-1-last-inspection
File m1/za/17-gmp/171-last-inspection/last-inspection-VAR.EXT
Comment
68 Number 1.7.2
Title Inspection reports or equivalent document
Element m1-7-2-inspection-report-or-equivalent
Directory m1/za/17-gmp/172-inspection-report-or-equivalent
Comment
69 Number 1.7.2
Title Inspection reports or equivalent document
Element m1-7-2-inspection-report-or-equivalent
File m1/za/17-gmp/172-inspection-report-or-equivalent/inspection-report-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 29 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

70 Number 1.7.3
Title Latest GMP certificate or a copy of the appropriate licence
Element m1-7-3-gmp-certificate
Directory m1/za/17-gmp/173-gmp-certificate
Comment
71 Number 1.7.3
Title Latest GMP certificate or a copy of the appropriate licence
Element m1-7-3-gmp-certificate
File m1/za/17-gmp/173-gmp-certificate/gmp-certificate-VAR.EXT
Comment
72 Number 1.7.4
Title Release
Element m1-7-4-release
Directory m1/za/17-gmp/174-release
Comment General placeholder for specific requirements information
73 Number 1.7.4.1
Title API
Element m1-7-4-1-api
Directory m1/za/17-gmp/174-release/1741-api
Comment
74 Number 1.7.4.1
Title API
Element m1-7-4-1-api
File m1/za/17-gmp/174-release/1741-api/api-VAR.EXT
Comment Identification and assay of the API will be performed irrespective of the possession of a CoA from the manufacturer

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 30 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

75 Number 1.7.4.2
Title IPIs
Element m1-7-4-2-ipi
Directory m1/za/17-gmp/174-release/1742-ipi
Comment
76 Number 1.7.4.2
Title IPIs
Element m1-7-4-2-ipi
File m1/za/17-gmp/174-release/1742-ipi/ipi-VAR.EXT
Comment Identification of the IPI will be performed irrespective of the possession of a CoA from the manufacturer
77 Number 1.7.4.3
Title Finished Product Release Control (FPRC) tests
Element m1-7-4-3-fprc-tests
Directory m1/za/17-gmp/174-release/1743-fprc-tests
Comment
78 Number 1.7.4.3
Title Finished Product Release Control (FPRC) tests
Element m1-7-4-3-fprc-tests
File m1/za/17-gmp/174-release/1743-fprc-tests/fprc-tests-VAR.EXT
Comment For imported products at least the identification and assay of the API content should be performed by an approved laboratory (FPRC)
after importation
79 Number 1.7.4.4
Title Finished Product Release Responsibility (FPRR) criteria
Element m1-7-4-4-fprr-criteria
Directory m1/za/17-gmp/174-release/1744-fprr-criteria
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 31 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

80 Number 1.7.4.4
Title Finished Product Release Responsibility (FPRR) criteria
Element m1-7-4-4-fprr-criteria
File m1/za/17-gmp/174-release/1744-fprr-criteria/fprr-criteria-VAR.EXT
Comment
81 Number 1.7.5
Title Confirmation of contract
Element m1-7-5-contract-confirmation
Directory m1/za/17-gmp/175-contract-confirmation
Comment Confirmation of technical contract between manufacturer/s, packer/s, FPRC/s and HCR/PHCR
82 Number 1.7.5
Title Confirmation of contract
Element m1-7-5-contract-confirmation
File m1/za/17-gmp/175-contract-confirmation/contract-confirmation-VAR.EXT
Comment
83 Number 1.7.6
Title CPP (WHO certification scheme)
Element m1-7-6-cpp
Directory m1/za/17-gmp/176-cpp
Comment
84 Number 1.7.6
Title CPP (WHO certification scheme)
Element m1-7-6-cpp
File m1/za/17-gmp/176-cpp/cpp-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 32 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

85 Number 1.7.7
Title SAPC registration
Element m1-7-7-sapc-reg
Directory m1/za/17-gmp/177-sapc-reg
Comment
86 Number 1.7.7
Title SAPC registration
Element m1-7-7-sapc-reg
File m1/za/17-gmp/177-sapc-reg/sapc-reg-VAR.EXT
Comment Proof of current registration of the Responsible Pharmacist by the SAPC in terms of Act 53 (Pharmacy Act), proof of current
registration of the pharmacist signing the dossier by the SAPC in terms of Act 53 (Pharmacy Act) (if different from the Responsible
Pharmacist), proof of registration of the Applicant/PHCR as a pharmacy or a pharmacist (read with guidelines)
87 Number 1.7.8
Title Registration with Registrar of Companies
Element m1-7-8-comp-reg
Directory m1/za/17-gmp/178-comp-reg
Comment
88 Number 1.7.8
Title Registration with Registrar of Companies
Element m1-7-8-comp-reg
File m1/za/17-gmp/178-comp-reg/comp-reg-VAR.EXT
Comment A copy of the certificate of registration of the company with the Registrar of Companies (if relevant)
89 Number 1.7.9
Title Other documents relating to the Applicant/PHCR
Element m1-7-9-docs-phcr
Directory m1/za/17-gmp/179-docs-phcr
Comment
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 33 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

90 Number 1.7.9
Title Other documents relating to the Applicant/PHCR
Element m1-7-9-docs-phcr
File m1/za/17-gmp/179-docs-phcr/phcr-VAR.EXT
Comment Letters of cession and acceptance, old and new company letterheads where applicable
91 Number 1.7.10
Title Sample and Documents
Element m1-7-10-sample-documents
Directory m1/za/17-gmp/1710-sample-documents
Comment
92 Number 1.7.10.1
Title Confirmation of submission of sample
Element m1-7-10-1-sample-submission-confirmation
Directory m1/za/17-gmp/1710-sample-documents/17101-sample-submission-confirmation
Comment
93 Number 1.7.10.1
Title Confirmation of submission of sample
Element m1-7-10-1-sample-submission-confirmation
File m1/za/17-gmp/1710-sample-documents/17101-sample-submission-confirmation/confirmation-sample-VAR.EXT
Comment
94 Number 1.7.10.2
Title Batch manufacturing record of the sample
Element m1-7-10-2-sample-bmr
Directory m1/za/17-gmp/1710-sample-documents/17102-sample-bmr
Comment Include information as per module 1
a) Confirmation of inclusion of batch manufacturing record in Module 3.2.R.7 or
b) Batch manufacturing record of the sample available for inspection
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 34 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

95 Number 1.7.10.2
Title Batch manufacturing record of the sample
Element m1-7-10-2-sample-bmr
File m1/za/17-gmp/1710-sample-documents/17102-sample-bmr/sample-bmr-VAR.EXT
Comment
96 Number 1.7.10.3
Title CoA of the sample
Element m1-7-10-3-sample-coa
Directory m1/za/17-gmp/1710-sample-documents/17103-sample-coa
Comment
97 Number 1.7.10.3
Title CoA of the sample
Element m1-7-10-3-sample-coa
File m1/za/17-gmp/1710-sample-documents/17103-sample-coa/sample-coa-VAR.EXT
Comment
98 Number 1.7.11
Title Certified copy of a permit to manufacture specified Schedule 5, Schedules 6, 7 and 8 substances
Element m1-7-11-manufacturing-permit
Directory m1/za/17-gmp/1711-manufacturing-permit
Comment
99 Number 1.7.11
Title Certified copy of a permit to manufacture specified Schedule 5, Schedules 6, 7 and 8 substances
Element m1-7-11-manufacturing-permit
File m1/za/17-gmp/1711-manufacturing-permit/manufacturing-permit-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 35 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

100 Number 1.7.12

Title Inspection flow diagram
Element m1-7-12-inspection-flow-diagram
Directory m1/za/17-gmp/1712-inspection-flow-diagram
Comment
101 Number 1.7.12
Title Inspection flow diagram
Element m1-7-12-inspection-flow-diagram
File m1/za/17-gmp/1712-inspection-flow-diagram/inspection-flow-diagram-VAR.EXT
Comment
102 Number 1.7.13
Title Organogram
Element m1-7-13-organogram
Directory m1/za/17-gmp/1713-organogram
Comment
103 Number 1.7.13
Title Organogram
Element m1-7-13-organogram
File m1/za/17-gmp/1713-organogram/organogram-VAR.EXT
Comment
104 Number 1.8
Title Details of compliance with screening outcomes
Element m1-8-compliance-screening
Directory m1/za/18-compliance-screening
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 36 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

105 Number 1.8

Title Details of compliance with screening outcomes
Element m1-8-compliance-screening
File m1/za/18-compliance-screening/compliance-screening-VAR.EXT
Comment
106 Number 1.9
Title Individual patient data - statement of availability
Element m1-9-indiv-patient-data
Directory m1/za/19-indiv-patient-data
Comment
107 Number 1.9
Title Individual patient data - statement of availability
Element m1-9-indiv-patient-data
File m1/za/19-indiv-patient-data/indiv-patient-data-VAR.EXT
Comment
108 Number 1.10
Title Foreign regulatory status
Element m1-10-foreign-reg-status
Directory m1/za/110-foreign-reg-status
Comment
109 Number 1.10.1
Title List of countries in which an application for the same product as being applied for has been submitted
Element m1-10-1-countries-same-appl
Directory m1/za/110-foreign-reg-status/1101-countries-same-appl
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 37 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

110 Number 1.10.1

Title List of countries in which an application for the same product as being applied for has been submitted
Element m1-10-1-countries-same-appl
File m1/za/110-foreign-reg-status/1101-countries-same-appl/countries-same-appl-VAR.EXT
Comment
111 Number 1.10.2
Title Registration certificate or marketing authorisation
Element m1-10-2-foreign-reg-certif-or-ma
Directory m1/za/110-foreign-reg-status/1102-foreign-reg-certif-or-ma
Comment
112 Number 1.10.2
Title Registration certificate or marketing authorisation
Element m1-10-2-foreign-reg-certif-or-ma
File m1/za/110-foreign-reg-status/1102-foreign-reg-certif-or-ma/foreign-reg-cert-or-ma-VAR.EXT
Comment
113 Number 1.10.3
Title Foreign prescribing and patient information
Element m1-10-3-foreign-pi
Directory m1/za/110-foreign-reg-status/1103-foreign-pi
Comment
114 Number 1.10.3
Title Foreign prescribing and patient information
Element m1-10-3-foreign-pi
File m1/za/110-foreign-reg-status/1103-foreign-pi/foreign-pi-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 38 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

115 Number 1.10.4

Title Data set similarities
Element m1-10-4-data-set-similarities
Directory m1/za/110-foreign-reg-status/1104-data-set-similarities
Comment
116 Number 1.10.4
Title Data set similarities
Element m1-10-4-data-set-similarities
File m1/za/110-foreign-reg-status/1104-data-set-similarities/data-set-similarities-VAR.EXT
Comment
117 Number 1.11
Title Bioequivalence trial information
Element m1-11-be-trial-info
Directory m1/za/111-be-trial-info
Comment
118 Number 1.11
Title Bioequivalence trial information
Element m1-11-be-trial-info
File m1/za/111-be-trial-info/be-trial-info-VAR.EXT
Comment
119 Number 1.12
Title Paediatric development programme
Element m1-12-paediatric-dev-program
Directory m1/za/112-paediatric-dev-program
Comment For future use

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 39 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

120 Number 1.12

Title Paediatric development programme
Element m1-12-paediatric-dev-program
File m1/za/112-paediatric-dev-program/paediatric-dev-program-VAR.EXT
Comment
121 Number 1.13
Title Risk management plan
Element m1-13-risk-management-plan
Directory m1/za/113-risk-management-plan
Comment
122 Number 1.13
Title Risk management plan
Element m1-13-risk-management-plan
File m1/za/113-risk-management-plan/risk-management-plan-VAR.EXT
Comment

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 40 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Appendix 2: Envelope Element Description

The “za-envelope” element is the root element that defines metadata of the submission. This element may contain several envelope entries.

Element Attribute Description/Instructions Constraint Occurrence

za-envelope Root element that provides metadata for the submission. Mandatory Unique

application-number This is the number issued for the product by the MCC and remains Mandatory Repeatable
for the full lifecycle of the product from the first data submission.

applicant The name of the applicant/HCR submitting the eCTD. Mandatory Unique

proprietary-name The name of the medicinal product. Include even if not yet Mandatory Repeatable
approved.

dosage-form The dosage form of the medicinal product. Mandatory Repeatable

inn The INN of the API(s) accompanied by its salt or hydrate form (if Mandatory Repeatable
relevant) or chemical description of the API(s).

ectd-sequence-number This is the sequence number of the data submission – this should Mandatory Unique
start at 0000 for the initial data submission lodged as an eCTD, and
then increase incrementally with each subsequent data submission
related to the same product e.g. 0000, 0001, 0002, 0003.

related-ectd-sequence- This is the sequence number of a previous submission to which this Optional Repeatable
number submission relates (e.g. Response to pre-reg recommendation).

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 41 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Element Attribute Description/Instructions Constraint Occurrence

submission Provides administrative information associated with the submission. Mandatory Repeatable

type The type of regulatory submission that this data submission relates Mandatory Unique
to.
The following are the valid values:

 New application, including:

• na-nce-ph: New Chemical Entity - Pharmaceutical
• na-nce-b: New Chemical Entity - Biological
• na-ms: Multisource
• na-bs: Biosimilar
• na-le: Line extension
• na-cu: Call-up
• na-cm: Complementary Medicines

 Response to pre-reg recommendation:

• pre-reg-pa: Pharmaceutical and Analytical
• pre-reg-cl: Clinical
• pre-reg-pn: Proprietary name
• pre-reg-sch: Scheduling
• pre-reg-insp: Inspectorate
• pre-reg-biol: Biological committee response
• pre-reg-cm: Complementary Medicines
• pre-reg-cr: Response to Council resolutions

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 42 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Element Attribute Description/Instructions Constraint Occurrence

type  Post-registration: Mandatory Unique

• post-reg-insp: Inspectorate
• post-reg-pa: Pharmaceutical and Analytical
• post-reg-cl: Clinical
• post-reg-pn: Proprietary name change application
• post-reg-pn-update: Updates following a proprietary name
change approval
• post-reg-hcr: Applicant transfer, name and address change
of applicant
• post-reg-biol: Biologicals and biosimilars
• post-reg-cm: Complementary Medicines
 Response to post-registration recommendation:
• resp-post-reg-insp: Inspectorate
• resp-post-reg-pa: Pharmaceutical and Analytical
• resp-post-reg-cl: Clinical
• resp-post-reg-pn: Proprietary name change application
• resp-post-reg-pn-update: Updates following a proprietary
name change approval
• resp-post-reg-hcr: Applicant transfer, name and address
change of applicant
• resp-post-reg-biol: Biologicals and biosimilars
• resp-post-reg-cm: Complementary Medicines

 Withdrawal / cancellation
• withdrawal: Withdrawal of a submission
• cancellation: Cancellation of a registered product
 Baseline submissions
• baseline: Reformatting from Paper to eCTD

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 43 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Element Attribute Description/Instructions Constraint Occurrence

submission/efficacy Proof of efficacy Mandatory Repeatable

data-type The data type submitted as proof of efficacy Mandatory Unique
• non-cl: Non-clinical
• cl: Clinical
• be: Bioequivalence study
• other: Other
• na: Not applicable

description A description should be provided if the data type is set to <other> Optional Unique

multiple-applications Optional Repeatable

proprietary-names The name of the multiple / duplicate applications of the medicinal Mandatory Unique
product. Include even if the name not yet approved.

application-numbers The application number/s of the duplicate applications. Mandatory Unique

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 44 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Example of the use of the Related Sequence

The related sequence number describes the relationship of additional information to the original submission or subsequent submissions.
An illustration of how the related sequence number is used to describe the relationship of additional information to the original and subsequent
submissions follows.

Table 6: Example of how the Related Sequence should be used

Sequence Submission Submission Description Related Submission Comment

Type eCTD Type
Sequence Related
Sequence
0000 na-nce-ph New medicine application for a NCE <none> <none> This sequence is a new regulatory activity (New
pharmaceutical medicine application) and so no related
sequence is included
0001 pre-reg-pn Response to Proprietary Name 0000 na-nce-ph This is a continuation of the regulatory activity
recommendation for the NCE initiated in 0000 and so the related eCTD
sequence points to the beginning of that
regulatory activity
0002 pre-reg-pa Response to P&A recommendation for 0000 na-nce-ph This is a continuation of the regulatory activity
the NCE initiated in 0000 and so the related eCTD
sequence points to the beginning of that
regulatory activity
0003 pre-reg-cl Response to Clinical recommendation 0000 na-nce-ph This is a continuation of the regulatory activity
for the NCE 0002 pre-reg-pa initiated in 0000 and includes P&A labelling
recommendations and so the related eCTD
sequence points to the beginning of that
regulatory activity as well as the P&A response
0004 pre-reg-pa Response to second P&A 0000 na-nce-ph This is a continuation of the regulatory activity
recommendation for the NCE 0001 pre-reg-pn initiated in 0000 and 0002 and includes the
approved amended proprietary name, and so the
0002 pre-reg-pa
related eCTD sequence points to the beginning
of that regulatory activity, the first P&A response,
as well as the Proprietary Name response

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 45 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Sequence Submission Submission Description Related Submission Comment

Type eCTD Type
Sequence Related
Sequence
0005 pre-reg-cl Response to second Clinical 0000 na-nce-ph This is a continuation of the regulatory activity
recommendation for the NCE 0001 pre-reg-pn initiated in 0000 and 0003 and includes the
approved amended proprietary name, and
0003 pre-reg-cl
includes P&A labelling recommendations, so the
0004 pre-reg-pa related eCTD sequence points to the beginning
of that activity, the first Clinical response, second
P&A response, as well as the Proprietary Name
response
0006 post-reg-pa Application for shelf-life extension of the <none> <none> This is a new regulatory activity and so no related
NCE eCTD sequence is included
0007 post-reg-cl Application for a new indication for the <none> <none> This is a new regulatory activity and so no related
NCE eCTD sequence is included
0008 post-reg-pa Application for an additional API <none> <none> This is a new regulatory activity and so no related
manufacturer for the NCE eCTD sequence is included
0009 resp-post- Response to P&A recommendation on 0006 post-reg-pa This is a continuation of the regulatory activity
reg-pa the shelf-life extension for the NCE initiated in 0006 and so the related eCTD
sequence points to the beginning of that activity
0010 resp-post- Response to P&A recommendation on 0008 post-reg-pa This is a continuation of the regulatory activity
reg-pa the additional API manufacturer for the initiated in 0008and so the related eCTD
NCE sequence points to the beginning of that activity
0011 resp-post- Response to Clinical recommendation on 0007 post-reg-cl This is a continuation of the regulatory activity
reg-cl the new indication for the NCE initiated in 0007 and so the related eCTD
sequence points to the beginning of that activity

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 46 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Appendix 3: Example Screenshots

This appendix is included to demonstrate how the envelope and directory structure may appear.
Structure of the Envelope

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 47 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Directory Structure – Part 1

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 48 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Directory Structure – Part 2

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 49 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Appendix 4: Creating the XML ZA Submission

Details of the name used for the root directory (eCTD identifier) should always be included in the letter of
application. The new application and subsequent submissions should use the same top-level directory name.
Each submission should be differentiated by a sub-directory named according to the eCTD Sequence number
of the submission to the authority. The application number and eCTD Sequence number should be included
in the “za-envelope” element of the ZA Regional instance. The first sub-directory below the top-level directory
for the original submission should have the eCTD Sequence number “0000” and e.g. the three subsequent
submissions respectively "0001", "0002" and "0003".

See 2.23 Guidance for the submission of regulatory information in eCTD format, relevant section, for further
information on the eCTD identifier.

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 50 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

Appendix 5: Modularised DTD for ZA Module 1

za-regional.dtd:
<!--
MCC ZA Regional DTD M1
Version: 2.1
State: final
Date: 08/11/2016
Authors: EXTEDO
Reference: ZA eCTD Module 1 Technical Specification v2.1

Meaning of the suffixes:

? : element is optional; must appear 0 or 1 time
* : element is optional; must appear 0 or more times
+ : element is mandatory; must appear 1 or more times
<none> : element is mandatory; must appear once and only once
-->

<!ENTITY % leaf-node "(( leaf | node-extension )*)">

<!ENTITY % envelope-module SYSTEM "za-envelope.mod">
%envelope-module;
<!ENTITY % leaf-module SYSTEM "za-leaf.mod">
%leaf-module;

<!ELEMENT mcc:za-backbone (
za-envelope,
m1-za
)>
<!ATTLIST mcc:za-backbone
xmlns:mcc CDATA #FIXED "http://www.mccza.com"
xmlns:xlink CDATA #FIXED "http://www.w3c.org/1999/xlink"
dtd-version CDATA #FIXED "2.1"
xml:lang CDATA #IMPLIED
>

<!ELEMENT m1-za (
m1-0-application-letter,
m1-2-application?,
m1-3-za-labelling-packaging?,
m1-4-expert-information?,
m1-5-specific-requirements?,
m1-6-environ-risk-assessment?,
m1-7-gmp?,
m1-8-compliance-screening?,
m1-9-indiv-patient-data?,
m1-10-foreign-reg-status?,
m1-11-be-trial-info?,

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 51 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

m1-12-paediatric-dev-program?,
m1-13-risk-management-plan?
)>

<!ELEMENT m1-0-application-letter (%leaf-node;)>

<!ELEMENT m1-2-application (
m1-2-1-application-form?,
m1-2-2-annexes?
)>

<!ELEMENT m1-2-1-application-form (%leaf-node;)>

<!ELEMENT m1-2-2-annexes (
m1-2-2-1-proof-of-payment?,
m1-2-2-2-letter-of-authorisation?,
m1-2-2-3-dossier-product-batch-information?,
m1-2-2-4-electronic-copy-declaration?,
m1-2-2-5-cv-pharmacovigilance?,
m1-2-2-6-api-change-control?,
m1-2-2-7-vamf-certificate?,
m1-2-2-8-pmf-certificate?
)>

<!ELEMENT m1-2-2-1-proof-of-payment (%leaf-node;)>

<!ELEMENT m1-2-2-2-letter-of-authorisation (%leaf-node;)>

<!ELEMENT m1-2-2-3-dossier-product-batch-information (%leaf-node;)>

<!ELEMENT m1-2-2-4-electronic-copy-declaration (%leaf-node;)>

<!ELEMENT m1-2-2-5-cv-pharmacovigilance (%leaf-node;)>

<!ELEMENT m1-2-2-6-api-change-control (%leaf-node;)>

<!ELEMENT m1-2-2-7-vamf-certificate (%leaf-node;)>

<!ELEMENT m1-2-2-8-pmf-certificate (%leaf-node;)>

<!ELEMENT m1-3-za-labelling-packaging (
m1-3-1-sapi?,
m1-3-2-pil?,
m1-3-3-labels?,
m1-3-4-braille?
)>

<!ELEMENT m1-3-1-sapi (
m1-3-1-1-pi?,
m1-3-1-2-stdrefs?
)>
<!ELEMENT m1-3-1-1-pi (%leaf-node;)>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 52 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

<!ELEMENT m1-3-1-2-stdrefs (%leaf-node;)>

<!ELEMENT m1-3-2-pil (%leaf-node;)>

<!ELEMENT m1-3-3-labels (%leaf-node;)>

<!ELEMENT m1-3-4-braille (%leaf-node;)>

<!ELEMENT m1-4-expert-information (
m1-4-1-quality?,
m1-4-2-non-clinical?,
m1-4-3-clinical?
)>
<!ELEMENT m1-4-1-quality (%leaf-node;)>
<!ELEMENT m1-4-2-non-clinical (%leaf-node;)>
<!ELEMENT m1-4-3-clinical (%leaf-node;)>

<!ELEMENT m1-5-specific-requirements (
m1-5-1-literature-based?,
m1-5-2-amendment?,
m1-5-3-proprietary-name?,
m1-5-4-gmo?,
m1-5-5-pi-amendment?
)>

<!ELEMENT m1-5-1-literature-based (%leaf-node;)>

<!ELEMENT m1-5-2-amendment (
m1-5-2-1-amendment-schedule?,
m1-5-2-2-medicine-register?,
m1-5-2-3-affidavit?
)>
<!ELEMENT m1-5-2-1-amendment-schedule (%leaf-node;)>
<!ELEMENT m1-5-2-2-medicine-register (%leaf-node;)>
<!ELEMENT m1-5-2-3-affidavit (%leaf-node;)>

<!ELEMENT m1-5-3-proprietary-name (%leaf-node;)>

<!ELEMENT m1-5-4-gmo (%leaf-node;)>

<!ELEMENT m1-5-5-pi-amendment (%leaf-node;)>

<!ELEMENT m1-6-environ-risk-assessment (
m1-6-1-nongmo?,
m1-6-2-gmo?
)>
<!ELEMENT m1-6-1-nongmo (%leaf-node;)>
<!ELEMENT m1-6-2-gmo (%leaf-node;)>

<!ELEMENT m1-7-gmp (
m1-7-1-last-inspection?,

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 53 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

m1-7-2-inspection-report-or-equivalent?,
m1-7-3-gmp-certificate?,
m1-7-4-release?,
m1-7-5-contract-confirmation?,
m1-7-6-cpp?,
m1-7-7-sapc-reg?,
m1-7-8-comp-reg?,
m1-7-9-docs-phcr?,
m1-7-10-sample-documents?,
m1-7-11-manufacturing-permit?,
m1-7-12-inspection-flow-diagram?,
m1-7-13-organogram?
)>

<!ELEMENT m1-7-1-last-inspection (%leaf-node;)>

<!ELEMENT m1-7-2-inspection-report-or-equivalent (%leaf-node;)>

<!ELEMENT m1-7-3-gmp-certificate (%leaf-node;)>

<!ELEMENT m1-7-4-release (
m1-7-4-1-api?,
m1-7-4-2-ipi?,
m1-7-4-3-fprc-tests?,
m1-7-4-4-fprr-criteria?
)>
<!ELEMENT m1-7-4-1-api (%leaf-node;)>
<!ELEMENT m1-7-4-2-ipi (%leaf-node;)>
<!ELEMENT m1-7-4-3-fprc-tests (%leaf-node;)>
<!ELEMENT m1-7-4-4-fprr-criteria (%leaf-node;)>

<!ELEMENT m1-7-5-contract-confirmation (%leaf-node;)>

<!ELEMENT m1-7-6-cpp (%leaf-node;)>

<!ELEMENT m1-7-7-sapc-reg (%leaf-node;)>

<!ELEMENT m1-7-8-comp-reg (%leaf-node;)>

<!ELEMENT m1-7-9-docs-phcr (%leaf-node;)>

<!ELEMENT m1-7-10-sample-documents (
m1-7-10-1-sample-submission-confirmation?,
m1-7-10-2-sample-bmr?,
m1-7-10-3-sample-coa?
)>
<!ELEMENT m1-7-10-1-sample-submission-confirmation (%leaf-node;)>
<!ELEMENT m1-7-10-2-sample-bmr (%leaf-node;)>
<!ELEMENT m1-7-10-3-sample-coa (%leaf-node;)>

<!ELEMENT m1-7-11-manufacturing-permit (%leaf-node;)>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 54 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

<!ELEMENT m1-7-12-inspection-flow-diagram (%leaf-node;)>

<!ELEMENT m1-7-13-organogram (%leaf-node;)>

<!ELEMENT m1-8-compliance-screening (%leaf-node;)>

<!ELEMENT m1-9-indiv-patient-data (%leaf-node;)>

<!ELEMENT m1-10-foreign-reg-status (
m1-10-1-countries-same-appl?,
m1-10-2-foreign-reg-certif-or-ma?,
m1-10-3-foreign-pi?,
m1-10-4-data-set-similarities?
)>

<!ELEMENT m1-10-1-countries-same-appl (%leaf-node;)>

<!ELEMENT m1-10-2-foreign-reg-certif-or-ma (%leaf-node;)>

<!ELEMENT m1-10-3-foreign-pi (%leaf-node;)>

<!ELEMENT m1-10-4-data-set-similarities (%leaf-node;)>

<!ELEMENT m1-11-be-trial-info (%leaf-node;)>

<!ELEMENT m1-12-paediatric-dev-program (%leaf-node;)>

<!ELEMENT m1-13-risk-management-plan (%leaf-node;)>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 55 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

za-envelope.mod:
<!--
MCC ZA Regional Envelope MOD
Version: 2.1
State: final
Date: 08/11/2016
Authors: EXTEDO

Meaning of the suffixes:

<!ELEMENT za-envelope (
application-number+,
applicant,
proprietary-name+,
dosage-form+,
inn+,
ectd-sequence-number,
related-ectd-sequence-number*,
submission+,
multiple-applications*
)>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 56 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 57 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

za-leaf.mod:

<!--
MCC ZA Regional Leaf MOD
Version: 2.1
State: final
Date: 08/11/2016
Authors: EXTEDO

Meaning of the suffixes:

<!ELEMENT node-extension (title, (leaf | node-extension)+)>
<!ATTLIST node-extension
ID ID #IMPLIED
xml:lang CDATA #IMPLIED
>

<!ENTITY % show-list " (new | replace | embed | other | none) ">
<!ENTITY % actuate-list " (onLoad | onRequest | other | none) ">
<!ENTITY % operation-list " (new | append | replace | delete) ">
<!ENTITY % leaf-element " (title, link-text?) ">
<!ENTITY % leaf-att '
ID ID #REQUIRED
application-version CDATA #IMPLIED
version CDATA #IMPLIED
font-library CDATA #IMPLIED
operation %operation-list; #REQUIRED
modified-file CDATA #IMPLIED
checksum CDATA #REQUIRED
checksum-type CDATA #REQUIRED
keywords CDATA #IMPLIED
xmlns:xlink CDATA #FIXED "http://www.w3c.org/1999/xlink"
xlink:type CDATA #FIXED "simple"
xlink:role CDATA #IMPLIED
xlink:href CDATA #IMPLIED
xlink:show %show-list; #IMPLIED
xlink:actuate %actuate-list; #IMPLIED
xml:lang CDATA #IMPLIED
'>
<!ELEMENT leaf %leaf-element;>
<!ATTLIST leaf
%leaf-att;
>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link-text (#PCDATA | xref)*>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 58 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

<!ELEMENT xref EMPTY>

<!ATTLIST xref
ID ID #REQUIRED
xmlns:xlink CDATA #FIXED "http://www.w3c.org/1999/xlink"
xlink:type CDATA #FIXED "simple"
xlink:role CDATA #IMPLIED
xlink:title CDATA #REQUIRED
xlink:href CDATA #REQUIRED
xlink:show %show-list; #IMPLIED
xlink:actuate %actuate-list; #IMPLIED
>

>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 Nov 2016 Page 59 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

za-regional.xsl:
<?xml version="1.0" encoding="iso-8859-1" standalone="no"?>

<xsl:stylesheet version="2.1"
xmlns:xsl="http://www.w3.org/1999/XSL/Transform"
xmlns:mcc="http://www.mccza.com"
xmlns:xlink="http://www.w3c.org/1999/xlink">

<xsl:output method="html" encoding="UTF-8" indent="no"/>

<xsl:template match="/">
<html>
<head>
<title>MCC ZA Module 1 - DTD version <xsl:value-of select="/mcc:za-backbone/@dtd-version"/></title>
<style type="text/css">
h1, h2, h3, h4 {margin-top:3pt ; margin-bottom:0pt}
ul {margin-bottom:0pt ; margin-top:0pt}
</style>
</head>
<body>
<center>
<h1>MCC ZA Module 1</h1>
<small>DTD version <xsl:value-of select="/mcc:za-backbone/@dtd-version"/></small>
</center>
<xsl:apply-templates select="//za-envelope"/>
<br/>
<xsl:apply-templates select="//m1-za"/>
</body>
</html>
</xsl:template>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 60 of 79

Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification

<xsl:template match="|@" mode="data">

<xsl:value-of select="."/>
</xsl:template>

<xsl:template match="|@" mode="csv">

<xsl:value-of select="."/>
<xsl:if test="position() != last()"><xsl:text>, </xsl:text></xsl:if>
</xsl:template>

<xsl:template match="|@" mode="submission-type">

<xsl:choose>
<xsl:when test="@type='na-nce-ph'">New Application - New Chemical Entity - Pharmaceutical</xsl:when>
<xsl:when test="@type='na-nce-b'">New Application - New Chemical Entity - Biological</xsl:when>
<xsl:when test="@type='na-ms'">New Application - Multisource</xsl:when>
<xsl:when test="@type='na-bs'">New Application - Biosimilar</xsl:when>
<xsl:when test="@type='na-le'">New Application - Line Extension</xsl:when>
<xsl:when test="@type='na-cu'">New Application - Call Up</xsl:when>
<xsl:when test="@type='na-cm'">New Application - Complementary Medicines</xsl:when>
<xsl:when test="@type='pre-reg-pa'">Response to pre-reg recommendation - Pharmaceutical and Analytical</xsl:when>
<xsl:when test="@type='pre-reg-cl'">Response to pre-reg recommendation - Clinical</xsl:when>
<xsl:when test="@type='pre-reg-pn'">Response to pre-reg recommendation - Proprietary name</xsl:when>
<xsl:when test="@type='pre-reg-sch'">Response to pre-reg recommendation - Scheduling</xsl:when>
<xsl:when test="@type='pre-reg-insp'">Response to pre-reg recommendation - Inspectorate</xsl:when>
<xsl:when test="@type='pre-reg-biol'">Response to pre-reg recommendation - Biological committee response</xsl:when>
<xsl:when test="@type='pre-reg-cm'">Response to pre-reg recommendation - Complementary Medicines</xsl:when>
<xsl:when test="@type='pre-reg-cr'">Response to pre-reg recommendation - Response to Council resolutions</xsl:when>
<xsl:when test="@type='post-reg-insp'">Post-registration - Inspectorate</xsl:when>
<xsl:when test="@type='post-reg-pa'">Post-registration - Pharmaceutical and Analytical</xsl:when>
<xsl:when test="@type='post-reg-cl'">Post-registration - Clinical</xsl:when>
<xsl:when test="@type='post-reg-pn'">Post-registration - Proprietary name change application</xsl:when>
<xsl:when test="@type='post-reg-pn-update'">Post-registration - Updates following a proprietary name change
approval</xsl:when>
<xsl:when test="@type='post-reg-hcr'">Post-registration - Applicant transfer, name and address change of applicant</xsl:when>
<xsl:when test="@type='post-reg-biol'">Post-registration - Biologicals and biosimilars</xsl:when>
<xsl:when test="@type='post-reg-cm'">Post-registration - Complementary Medicines</xsl:when>
<xsl:when test="@type='resp-post-reg-insp'">Response to Post-registration - Inspectorate</xsl:when>
<xsl:when test="@type='resp-post-reg-pa'">Response to Post-registration - Pharmaceutical and Analytical</xsl:when>
<xsl:when test="@type='resp-post-reg-cl'">Response to Post-registration - Clinical</xsl:when>
<xsl:when test="@type='resp-post-reg-pn'">Response to Post-registration - Proprietary name change application</xsl:when>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 61 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<xsl:when test="@type='resp-post-reg-pn-update'">Response to Post-registration - Updates following a proprietary name change
approval</xsl:when>
<xsl:when test="@type='resp-post-reg-hcr'">Response to Post-registration - Applicant transfer, name and address change of
applicant</xsl:when>
<xsl:when test="@type='resp-post-reg-biol'">Response to Post-registration - Biologicals and biosimilars</xsl:when>
<xsl:when test="@type='resp-post-reg-cm'">Response to Post-registration - Complementary Medicines</xsl:when>
<xsl:when test="@type='withdrawal'">Withdrawal of a submission</xsl:when>
<xsl:when test="@type='cancellation'">Cancellation of a registered product</xsl:when>
<xsl:when test="@type='baseline'">Reformatting from Paper to eCTD</xsl:when>
</xsl:choose>
</xsl:template>

<xsl:template match="|@" mode="efficacy">

<xsl:choose>
<xsl:when test="@data-type='non-cl'">Non-clinical</xsl:when>
<xsl:when test="@data-type='cl'">Clinical</xsl:when>
<xsl:when test="@data-type='be'">Bioequivalence Study</xsl:when>
<xsl:when test="@data-type='other'">Other<xsl:text>: </xsl:text>
<xsl:if test="@description">
<xsl:value-of select="@description"/>
</xsl:if>
</xsl:when>
<xsl:when test="@data-type='na'">Not applicable</xsl:when>
<xsl:otherwise>???</xsl:otherwise>
</xsl:choose>
<xsl:if test="position() != last()"><xsl:text>, </xsl:text></xsl:if>
</xsl:template>

<xsl:template match="|@" mode="submission">

<tr>
<td>
<xsl:apply-templates select="." mode="submission-type"/>
</td>
<td>
<xsl:text> / </xsl:text>
</td>
<td>
<xsl:apply-templates select="./efficacy" mode="efficacy"/>
</td>
</tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 62 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</xsl:template>

<xsl:template match="|@" mode="multiapp">

<xsl:template match="za-envelope">
<center>
<table width="90%" border="1px" frame="border" rules="groups" cellpadding="2" cellspacing="0">
<tr>
<td colspan="2"><h3>ZA Envelope</h3></td>
</tr>
<tr>
<td width="25%">Application Number: </td>
<td><xsl:apply-templates select="application-number" mode="csv"/></td>
</tr>
<tr>
<td>Applicant: </td>
<td><xsl:apply-templates select="applicant" mode="data"/></td>
</tr>
<tr>
<td>
Submission:<br/>
<small>(Type / Proof of Efficacy)</small>
</td>
<td>
<table>
<xsl:apply-templates select="submission" mode="submission"/>
</table>
</td>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 63 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</tr>
<tr>
<td>Proprietary Name: </td>
<td><xsl:apply-templates select="proprietary-name" mode="csv"/></td>
</tr>
<tr>
<td>Dosage Form: </td>
<td>
<xsl:apply-templates select="dosage-form" mode="csv"/>
</td>
</tr>
<tr>
<td>INN: </td>
<td><xsl:apply-templates select="inn" mode="csv"/></td>
</tr>
<tr>
<td>eCTD Sequence Number: </td>
<td><xsl:apply-templates select="ectd-sequence-number" mode="data"/></td>
</tr>
<tr>
<td>Related eCTD Sequence Number: </td>
<td><xsl:apply-templates select="related-ectd-sequence-number" mode="csv"/></td>
</tr>
<tr>
<td>
Multiple / Duplicate Applications:<br/>
<small>(Proprietary Names / Application Numbers)</small>
</td>
<td>
<table>
<xsl:apply-templates select="multiple-applications" mode="multiapp"/>
</table>
</td>
</tr>
</table>
</center>
</xsl:template>

<xsl:template match="leaf" mode="plain">

<a>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 64 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<xsl:attribute name="href"><xsl:value-of select="@xlink:href"/></xsl:attribute>
<xsl:value-of select="title"/>
</a>
<xsl:text> </xsl:text>
(<font color="red"><xsl:value-of select="@operation"/></font> - <font color="green"><xsl:value-of select="../@xml:lang"/></font>)
<xsl:if test="position() != last()"><br/></xsl:if>
</xsl:template>

<xsl:template match="leaf">
<li>
<a>
<xsl:attribute name="href"><xsl:value-of select="@xlink:href"/></xsl:attribute>
<xsl:value-of select="title"/>
</a>
<xsl:text> </xsl:text>
(<font color="red"><xsl:value-of select="@operation"/></font>)
<xsl:if test="position() != last()"><br/></xsl:if>
</li>
</xsl:template>

<xsl:template match="node-extension">
<li><xsl:apply-templates select="title" mode="data"/>
<ul type="square">
<xsl:apply-templates select="leaf | node-extension"/>
</ul>
</li>
</xsl:template>

<xsl:template match="m1-za">
<center>
<table width="90%" cellpadding="5" cellspacing="2">
<tr>
<td colspan="2"><h2>ZA Module 1</h2></td>
</tr>
<tr>
<td width="5%" valign="top"><h3>1.0</h3></td>
<td width="95%">
<h3>Letter of Application</h3>
<xsl:apply-templates select="m1-0-application-letter"/>
</td>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 65 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</tr>
<tr>
<td valign="top"><h3>1.2</h3></td>
<td>
<h3>Application</h3>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.2.1</h4>
</td>
<td>
<h4>Application Form</h4>
<xsl:apply-templates select="m1-2-application/m1-2-1-application-form"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.2.2</h4>
</td>
<td>
<h4>Annexes</h4>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.1</h5>
</td>
<td>
<h5>Proof of Payment</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-1-proof-of-payment"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.2</h5>
</td>
<td>
<h5>Letter of Authorisation</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-2-letter-of-authorisation"/>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 66 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.3</h5>
</td>
<td>
<h5>Dossier Product Batch Information</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-3-dossier-product-batch-
information"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.4</h5>
</td>
<td>
<h5>Electronic Copy Declaration</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-4-electronic-copy-declaration"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.5</h5>
</td>
<td>
<h5>Curriculum Vitae of the person responsible for pharmacovigilance</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-5-cv-pharmacovigilance"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.6</h5>
</td>
<td>
<h5>API change control</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-6-api-change-control"/>
</td>
</tr>
<tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 67 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<td valign="top">
<h5>1.2.2.7</h5>
</td>
<td>
<h5>EMA certificate for a Vaccine Antigen Master File (VAMF)</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-7-vamf-certificate"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.2.2.8</h5>
</td>
<td>
<h5>EMA certificate for a Plasma Master File (PMF)</h5>
<xsl:apply-templates select="m1-2-application/m1-2-2-annexes/m1-2-2-8-pmf-certificate"/>
</td>
</tr>
<tr>
<td valign="top"><h3>1.3</h3></td>
<td>
<h3>South African labelling and packaging</h3>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.3.1</h4>
</td>
<td>
<h4>South African Package Insert</h4>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.3.1.1</h5>
</td>
<td>
<h5>Package Insert</h5>
<xsl:apply-templates select="m1-3-za-labelling-packaging/m1-3-1-sapi/m1-3-1-1-pi"/>
</td>
</tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 68 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<tr>
<td valign="top">
<h5>1.3.1.2</h5>
</td>
<td>
<h5>Standard References</h5>
<xsl:apply-templates select="m1-3-za-labelling-packaging/m1-3-1-sapi/m1-3-1-2-stdrefs"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.3.2</h4>
</td>
<td>
<h4>Patient Information Leaflet</h4>
<xsl:apply-templates select="m1-3-za-labelling-packaging/m1-3-2-pil"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.3.3</h4>
</td>
<td>
<h4>Labels</h4>
<xsl:apply-templates select="m1-3-za-labelling-packaging/m1-3-3-labels"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.3.4</h4>
</td>
<td>
<h4>Braille</h4>
<xsl:apply-templates select="m1-3-za-labelling-packaging/m1-3-4-braille"/>
</td>
</tr>
<tr>
<td valign="top"><h3>1.4</h3></td>
<td>
<h3>Information about the experts</h3>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 69 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</td>
</tr>
<tr>
<td valign="top"><h4>1.4.1</h4></td>
<td>
<h4>Quality</h4>
<xsl:apply-templates select="m1-4-expert-information/m1-4-1-quality"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.4.2</h4></td>
<td>
<h4>Non-clinical</h4>
<xsl:apply-templates select="m1-4-expert-information/m1-4-2-non-clinical"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.4.3</h4></td>
<td>
<h4>Clinical</h4>
<xsl:apply-templates select="m1-4-expert-information/m1-4-3-clinical"/>
</td>
</tr>

<tr>
<td valign="top"><h3>1.5</h3></td>
<td>
<h3>Specific requirements for different types of applications</h3>
</td>
</tr>
<tr>
<td valign="top"><h4>1.5.1</h4></td>
<td>
<h4>Literature based submissions</h4>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-1-literature-based"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.5.2</h4></td>
<td>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 70 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<h4>Amendments/Variations</h4>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.5.2.1</h5>
</td>
<td>
<h5>Tabulated Schedule of Amendments</h5>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-2-amendment/m1-5-2-1-amendment-
schedule"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.5.2.2</h5>
</td>
<td>
<h5>Medicines Register Details</h5>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-2-amendment/m1-5-2-2-medicine-register"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.5.2.3</h5>
</td>
<td>
<h5>Affidavit by Responsible Pharmacist</h5>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-2-amendment/m1-5-2-3-affidavit"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.5.3</h4>
</td>
<td>
<h4>Proprietary name applications and changes</h4>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-3-proprietary-name"/>
</td>
</tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 71 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<tr>
<td valign="top">
<h4>1.5.4</h4>
</td>
<td>
<h4>Genetically Modified Organisms</h4>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-4-gmo"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.5.5</h4>
</td>
<td>
<h4>PI and PIL amendments/updates</h4>
<xsl:apply-templates select="m1-5-specific-requirements/m1-5-5-pi-amendment"/>
</td>
</tr>
<tr>
<td valign="top"><h3>1.6</h3></td>
<td>
<h3>Environmental Risk Assessment</h3>
</td>
</tr>
<tr>
<td valign="top"><h4>1.6.1</h4></td>
<td>
<h4>Non-GMO (Genetically Modified Organisms)</h4>
<xsl:apply-templates select="m1-6-environ-risk-assessment/m1-6-1-nongmo"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.6.2</h4>
</td>
<td>
<h4>GMO (Genetically Modified Organisms)</h4>
<xsl:apply-templates select="m1-6-environ-risk-assessment/m1-6-2-gmo"/>
</td>
</tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 72 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<tr>
<td valign="top"><h3>1.7</h3></td>
<td>
<h3>Good Manufacturing Practice</h3>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.1</h4></td>
<td>
<h4>Date of last inspection of each site</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-1-last-inspection"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.2</h4></td>
<td>
<h4>Inspection reports or equivalent document</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-2-inspection-report-or-equivalent"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.3</h4></td>
<td>
<h4>Latest GMP certificate or a copy of the appropriate licence</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-3-gmp-certificate"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.4</h4></td>
<td>
<h4>Release</h4>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.4.1</h5>
</td>
<td>
<h5>API</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-4-release/m1-7-4-1-api"/>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 73 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.4.2</h5>
</td>
<td>
<h5>IPIs</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-4-release/m1-7-4-2-ipi"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.4.3</h5>
</td>
<td>
<h5>Finished Product Release Control (FPRC) tests</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-4-release/m1-7-4-3-fprc-tests"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.4.4</h5>
</td>
<td>
<h5>Finished Product Release Responsibility (FPRR) criteria</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-4-release/m1-7-4-4-fprr-criteria"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.5</h4></td>
<td>
<h4>Confirmation of contract</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-5-contract-confirmation"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.6</h4></td>
<td>
<h4>CPP (WHO certification scheme)</h4>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 74 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<xsl:apply-templates select="m1-7-gmp/m1-7-6-cpp"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.7.7</h4>
</td>
<td>
<h4>SAPC registration</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-7-sapc-reg"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.8</h4></td>
<td>
<h4>Registration with Registrar of Companies</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-8-comp-reg"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.9</h4></td>
<td>
<h4>Other documents relating to the Applicant/PHCR</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-9-docs-phcr"/>
</td>
</tr>
<tr>
<td valign="top"><h4>1.7.10</h4></td>
<td>
<h4>Sample and Documents</h4>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.10.1</h5>
</td>
<td>
<h5>Confirmation of submission of sample</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-10-sample-documents/m1-7-10-1-sample-submission-
confirmation"/>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 75 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.10.2</h5>
</td>
<td>
<h5>Batch manufacturing record of the sample</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-10-sample-documents/m1-7-10-2-sample-bmr"/>
</td>
</tr>
<tr>
<td valign="top">
<h5>1.7.10.3</h5>
</td>
<td>
<h5>CoA of the sample</h5>
<xsl:apply-templates select="m1-7-gmp/m1-7-10-sample-documents/m1-7-10-3-sample-coa"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.7.11</h4>
</td>
<td>
<h4>Certified copy of a permit to manufacture specified Schedule 5, Schedules 6, 7 and 8 substances</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-11-manufacturing-permit"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.7.12</h4>
</td>
<td>
<h4>Inspection flow diagram</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-12-inspection-flow-diagram"/>
</td>
</tr>
<tr>
<td valign="top">
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 76 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<h4>1.7.13</h4>
</td>
<td>
<h4>Organogram</h4>
<xsl:apply-templates select="m1-7-gmp/m1-7-13-organogram"/>
</td>
</tr>
<tr>
<td valign="top"><h3>1.8</h3></td>
<td>
<h3>Details of compliance with screening outcomes</h3>
<xsl:apply-templates select="m1-8-compliance-screening"/>
</td>
</tr>
<tr>
<td valign="top">
<h3>1.9</h3>
</td>
<td>
<h3>Individual patient data - statement of availability</h3>
<xsl:apply-templates select="m1-9-indiv-patient-data"/>
</td>
</tr>
<tr>
<td valign="top">
<h3>1.10</h3>
</td>
<td>
<h3>Foreign regulatory status</h3>
</td>
</tr>
<tr>
<td valign="top"><h4>1.10.1</h4></td>
<td>
<h4>List of countries in which an application for the same product as being applied for has been
submitted</h4>
<xsl:apply-templates select="m1-10-foreign-reg-status/m1-10-1-countries-same-appl"/>
</td>
</tr>
<tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 77 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<td valign="top"><h4>1.10.2</h4></td>
<td>
<h4>Registration certificate or marketing authorisation</h4>
<xsl:apply-templates select="m1-10-foreign-reg-status/m1-10-2-foreign-reg-certif-or-ma"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.10.3</h4>
</td>
<td>
<h4>Foreign prescribing and patient information</h4>
<xsl:apply-templates select="m1-10-foreign-reg-status/m1-10-3-foreign-pi"/>
</td>
</tr>
<tr>
<td valign="top">
<h4>1.10.4</h4>
</td>
<td>
<h4>Data set similarities</h4>
<xsl:apply-templates select="m1-10-foreign-reg-status/m1-10-4-data-set-similarities"/>
</td>
</tr>
<tr>
<td valign="top"><h3>1.11</h3></td>
<td>
<h3>Bioequivalence trial information</h3>
<xsl:apply-templates select="m1-11-be-trial-info"/>
</td>
</tr>
<tr>
<td valign="top">
<h3>1.12</h3>
</td>
<td>
<h3>Paediatric development programme</h3>
<xsl:apply-templates select="m1-12-paediatric-dev-program"/>
</td>
</tr>
2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 78 of 79
Back to ToC
Registration of Medicines ZA eCTD Module 1 Technical Specification
<tr>
<td valign="top">
<h3>1.13</h3>
</td>
<td>
<h3>Risk management plan</h3>
<xsl:apply-templates select="m1-13-risk-management-plan"/>
</td>
</tr>
</table>
</center>
</xsl:template>

</xsl:stylesheet>

2.21_ZA_eCTD_Module_1_Technical_Sept16_v2.1 November 2016 Page 79 of 79

Back to ToC

Project Procurement Management Plan (PPMP) : Crossing Bayabas National High School
No ratings yet
Project Procurement Management Plan (PPMP) : Crossing Bayabas National High School
6 pages
Guideline Swiss Module 1 Specification For eCTD, Version 1.3, 01-Oct-2015
No ratings yet
Guideline Swiss Module 1 Specification For eCTD, Version 1.3, 01-Oct-2015
49 pages
eCTD Guidance v4 0-20160422-Final
No ratings yet
eCTD Guidance v4 0-20160422-Final
62 pages
The US OTC Drug Environment
No ratings yet
The US OTC Drug Environment
39 pages
RAC Drug Workshop Slides - EU 2022 - Questions and Answers
100% (1)
RAC Drug Workshop Slides - EU 2022 - Questions and Answers
67 pages
Affidavit of Poseur-Buyer
0% (1)
Affidavit of Poseur-Buyer
1 page
Pragmatism
No ratings yet
Pragmatism
15 pages
RAC Drug Workshop Slides - Global 2022 - Questions and Answers
100% (1)
RAC Drug Workshop Slides - Global 2022 - Questions and Answers
74 pages
ECTD Guidance v3.0 Final Aug13
No ratings yet
ECTD Guidance v3.0 Final Aug13
60 pages
My Childhood 6. My Childhood 6. My Childhood 6. My Childhood 6. My Childhood
No ratings yet
My Childhood 6. My Childhood 6. My Childhood 6. My Childhood 6. My Childhood
14 pages
Furnishings of Medieval English Peasant Houses
100% (2)
Furnishings of Medieval English Peasant Houses
7 pages
2.08 Variations Addendum For Human and Veterinary Medicines - v5 - 03.02.2022
No ratings yet
2.08 Variations Addendum For Human and Veterinary Medicines - v5 - 03.02.2022
38 pages
Double Layer Tile Press
100% (1)
Double Layer Tile Press
6 pages
Sahpra Biosimilars Medicines Guidance
No ratings yet
Sahpra Biosimilars Medicines Guidance
30 pages
Clinical Graphs Using SAS
From Everand
Clinical Graphs Using SAS
Sanjay Matange
No ratings yet
Ectd
No ratings yet
Ectd
28 pages
ICH Guidelines
50% (4)
ICH Guidelines
35 pages
1.5 eCTD v3.2
No ratings yet
1.5 eCTD v3.2
131 pages
CCS340 Cyber Security Lab
No ratings yet
CCS340 Cyber Security Lab
60 pages
Effect of Different Solvents On Extraction of Phenolic Antioxidants by Reflux Method From Wild Pomegranate Flavedo Their
No ratings yet
Effect of Different Solvents On Extraction of Phenolic Antioxidants by Reflux Method From Wild Pomegranate Flavedo Their
10 pages
A Very Sensitive Bioanalytical Method For The Estimation of Escitalopram in Rat Plasma Using Liquid Chromatography With
No ratings yet
A Very Sensitive Bioanalytical Method For The Estimation of Escitalopram in Rat Plasma Using Liquid Chromatography With
10 pages
Formulation and Evaluation of Flexible Liposome Embedded Emin Situem Thermoreversible Intranasal Gel of Rizatriptan Benz
No ratings yet
Formulation and Evaluation of Flexible Liposome Embedded Emin Situem Thermoreversible Intranasal Gel of Rizatriptan Benz
11 pages
Polity PYQ 2011-2023
No ratings yet
Polity PYQ 2011-2023
4 pages
Inhibitory Effect of Polyphyllin D On Proliferation of Human Colon Cancer Cell Line sw480 Emviaem The Microrna21phosphat
No ratings yet
Inhibitory Effect of Polyphyllin D On Proliferation of Human Colon Cancer Cell Line sw480 Emviaem The Microrna21phosphat
9 pages
ZA eCTD Module 1 Technical v1
No ratings yet
ZA eCTD Module 1 Technical v1
74 pages
Protective Effect of Polyherbal Extract On Gentamicininduced Renal Injury in Wistar Rats
No ratings yet
Protective Effect of Polyherbal Extract On Gentamicininduced Renal Injury in Wistar Rats
11 pages
Orange Book Preface - FDA
No ratings yet
Orange Book Preface - FDA
26 pages
And Aqueous Extracts of Anogeissus Latifolia Leaves
No ratings yet
And Aqueous Extracts of Anogeissus Latifolia Leaves
8 pages
Lab Tests
No ratings yet
Lab Tests
1 page
NETBACKUP White Paper
No ratings yet
NETBACKUP White Paper
20 pages
Maharashtra (PGA CET 2006)
No ratings yet
Maharashtra (PGA CET 2006)
24 pages
Chapter 2 Fundamental 1
No ratings yet
Chapter 2 Fundamental 1
28 pages
Glass - Craft - Final
No ratings yet
Glass - Craft - Final
65 pages
Food Allergy Thesis Statement
100% (1)
Food Allergy Thesis Statement
7 pages
ECTD How To Do Final
No ratings yet
ECTD How To Do Final
40 pages
Spring Reading Comprehension Worksheet
No ratings yet
Spring Reading Comprehension Worksheet
2 pages
CTD
No ratings yet
CTD
27 pages
2.23 Submission in eCTD Format v1
No ratings yet
2.23 Submission in eCTD Format v1
24 pages
CTD Notesdocx
No ratings yet
CTD Notesdocx
12 pages
Siklus Hidup Produk: (Product Life Cycle)
No ratings yet
Siklus Hidup Produk: (Product Life Cycle)
24 pages
Plan of Action To Prevent Human Extinction Risks
No ratings yet
Plan of Action To Prevent Human Extinction Risks
1 page
EU Orphan Medicinal Products
No ratings yet
EU Orphan Medicinal Products
1 page
Guidance Document
No ratings yet
Guidance Document
9 pages
How To Start A Conversation and Make Friends Revised and Updated Ebook Gabor, Don Amazon - Ca Kindle Store
No ratings yet
How To Start A Conversation and Make Friends Revised and Updated Ebook Gabor, Don Amazon - Ca Kindle Store
1 page
Instructiona L Design: Angelu Adlawan UDM-SN NR-41, GROUP 2
No ratings yet
Instructiona L Design: Angelu Adlawan UDM-SN NR-41, GROUP 2
17 pages
Fitness Lesson Plan
No ratings yet
Fitness Lesson Plan
5 pages
Log
No ratings yet
Log
79 pages
7.03 CAMs ZACTD Mar14 v2
No ratings yet
7.03 CAMs ZACTD Mar14 v2
22 pages
Essay On Addiction
100% (2)
Essay On Addiction
6 pages
Synerji
No ratings yet
Synerji
9 pages
O-TTPS: for ICT Product Integrity and Supply Chain Security – A Management Guide
From Everand
O-TTPS: for ICT Product Integrity and Supply Chain Security – A Management Guide
Sally Long
No ratings yet
THOMPSON, The New Visibility
No ratings yet
THOMPSON, The New Visibility
21 pages
Status of Molten Salt Reactor Technology
From Everand
Status of Molten Salt Reactor Technology
IAEA
No ratings yet
Written Report
No ratings yet
Written Report
9 pages
Reference Group and Voluntary Association
No ratings yet
Reference Group and Voluntary Association
8 pages
Atlas of Non-FDG PET–CT in Diagnostic Oncology
From Everand
Atlas of Non-FDG PET–CT in Diagnostic Oncology
IAEA
No ratings yet
List of Foreign Correspondents in The Spanish Civil War - Wikipedia
No ratings yet
List of Foreign Correspondents in The Spanish Civil War - Wikipedia
7 pages
eCTDHowtoDo - Final 201407 PDF
No ratings yet
eCTDHowtoDo - Final 201407 PDF
40 pages
PET-CT for the Management of Cancer Patients: A Review of the Existing Evidence
From Everand
PET-CT for the Management of Cancer Patients: A Review of the Existing Evidence
IAEA
No ratings yet
Clinical Applications of SPECT–CT
From Everand
Clinical Applications of SPECT–CT
IAEA
No ratings yet
2.23 Submission in eCTD Format Sept16 v2.1
No ratings yet
2.23 Submission in eCTD Format Sept16 v2.1
26 pages
Production, Quality Control and Clinical Applications of Radiosynovectomy Agents
From Everand
Production, Quality Control and Clinical Applications of Radiosynovectomy Agents
IAEA
No ratings yet
Nuclear Medicine Resources Manual 2020 Edition
From Everand
Nuclear Medicine Resources Manual 2020 Edition
IAEA
No ratings yet
Alternative Radionuclide Production with a Cyclotron
From Everand
Alternative Radionuclide Production with a Cyclotron
IAEA
No ratings yet
National Networks for Radiotherapy Dosimetry Audits
From Everand
National Networks for Radiotherapy Dosimetry Audits
IAEA
No ratings yet
Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications
From Everand
Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications
IAEA
No ratings yet
Consumable Cost Departement Wise APR@2021
No ratings yet
Consumable Cost Departement Wise APR@2021
4 pages
Pharmaceutical Packaging Technology: Pharmaceutical Packaging Technology
From Everand
Pharmaceutical Packaging Technology: Pharmaceutical Packaging Technology
U. K. Jain
3.5/5 (2)
Ideologyofpakistan
No ratings yet
Ideologyofpakistan
10 pages
Handbook of Basic Quality Control Tests for Diagnostic Radiology
From Everand
Handbook of Basic Quality Control Tests for Diagnostic Radiology
IAEA
No ratings yet
Medical Devices and IVDs: Fit for the new EU-Regulations: Your complete seminar for projekt, study and job
From Everand
Medical Devices and IVDs: Fit for the new EU-Regulations: Your complete seminar for projekt, study and job
Wolfgang Ecker
No ratings yet
Worldwide Implementation of Digital Mammography Imaging
From Everand
Worldwide Implementation of Digital Mammography Imaging
IAEA
No ratings yet
Multi-Objective Optimization in Chemical Engineering: Developments and Applications
From Everand
Multi-Objective Optimization in Chemical Engineering: Developments and Applications
Gade Pandu Rangaiah
No ratings yet
Nuclear Radiation Detection & Monitoring Instruments World Summary: Market Sector Values & Financials by Country
From Everand
Nuclear Radiation Detection & Monitoring Instruments World Summary: Market Sector Values & Financials by Country
Editorial DataGroup
No ratings yet
2.25 PA CTD Jun11 v3
No ratings yet
2.25 PA CTD Jun11 v3
38 pages
Training and Human Resource Considerations for Nuclear Facility Decommissioning
From Everand
Training and Human Resource Considerations for Nuclear Facility Decommissioning
IAEA
No ratings yet
Selecting Megavoltage Treatment Technologies in External Beam Radiotherapy
From Everand
Selecting Megavoltage Treatment Technologies in External Beam Radiotherapy
IAEA
No ratings yet
Nuclear Reactor Technology Assessment for Near Term Deployment
From Everand
Nuclear Reactor Technology Assessment for Near Term Deployment
IAEA
No ratings yet
Elementary Statistics 6th Edition Larson Solutions Manual
100% (69)
Elementary Statistics 6th Edition Larson Solutions Manual
26 pages
Dosimetry in Brachytherapy – An International Code of Practice for Secondary Standards Dosimetry Laboratories and Hospitals
From Everand
Dosimetry in Brachytherapy – An International Code of Practice for Secondary Standards Dosimetry Laboratories and Hospitals
IAEA
No ratings yet
Ageing Management for Nuclear Power Plants: International Generic Ageing Lessons Learned (IGALL)
From Everand
Ageing Management for Nuclear Power Plants: International Generic Ageing Lessons Learned (IGALL)
IAEA
No ratings yet
Implementation of a Remote and Automated Quality Control Programme for Radiography and Mammography Equipment
From Everand
Implementation of a Remote and Automated Quality Control Programme for Radiography and Mammography Equipment
IAEA
No ratings yet
Data Analysis and Collection for Costing of Research Reactor Decommissioning: Final Report of the DACCORD Collaborative Project
From Everand
Data Analysis and Collection for Costing of Research Reactor Decommissioning: Final Report of the DACCORD Collaborative Project
IAEA
No ratings yet
Mapping Organizational Competencies in Nuclear Organizations
From Everand
Mapping Organizational Competencies in Nuclear Organizations
IAEA
No ratings yet
Management of Ageing and Obsolescence of Instrumentation and Control Systems and Equipment in Nuclear Power Plants and Related Facilities Through Modernization
From Everand
Management of Ageing and Obsolescence of Instrumentation and Control Systems and Equipment in Nuclear Power Plants and Related Facilities Through Modernization
IAEA
No ratings yet
Human Factors Engineering Aspects of Instrumentation and Control System Design
From Everand
Human Factors Engineering Aspects of Instrumentation and Control System Design
IAEA
No ratings yet
International Safeguards in the Design of Reprocessing Plants
From Everand
International Safeguards in the Design of Reprocessing Plants
IAEA
No ratings yet
Establishing a Secondary Standards Dosimetry Laboratory
From Everand
Establishing a Secondary Standards Dosimetry Laboratory
IAEA
No ratings yet
Licensing Process for the Construction, Commissioning and Operation of Nuclear Power Plants
From Everand
Licensing Process for the Construction, Commissioning and Operation of Nuclear Power Plants
IAEA
No ratings yet
The Manufacture of Sterile Pharmaceuticals and Liquid Medical Devices Using Blow-Fill-Seal Technology: Points to Consider
From Everand
The Manufacture of Sterile Pharmaceuticals and Liquid Medical Devices Using Blow-Fill-Seal Technology: Points to Consider
K. Downey
No ratings yet
Developing Cost Estimates for Environmental Remediation Projects
From Everand
Developing Cost Estimates for Environmental Remediation Projects
IAEA
No ratings yet
Ageing Management and Long Term Operation of Nuclear Power Plants: Data Management, Scope Setting, Plant Programmes and Documentation
From Everand
Ageing Management and Long Term Operation of Nuclear Power Plants: Data Management, Scope Setting, Plant Programmes and Documentation
IAEA
No ratings yet
Methodologies for Assessing Pipe Failure Rates in Advanced Water Cooled Reactors
From Everand
Methodologies for Assessing Pipe Failure Rates in Advanced Water Cooled Reactors
IAEA
No ratings yet
Process Analytical Technology in Modern Manufacturing: Definitive Reference for Developers and Engineers
From Everand
Process Analytical Technology in Modern Manufacturing: Definitive Reference for Developers and Engineers
Richard Johnson
No ratings yet
Quality Assurance and Quality Control in Neutron Activation Analysis: A Guide to Practical Approaches
From Everand
Quality Assurance and Quality Control in Neutron Activation Analysis: A Guide to Practical Approaches
IAEA
No ratings yet
Digital Instrumentation and Control Systems for New and Existing Research Reactors
From Everand
Digital Instrumentation and Control Systems for New and Existing Research Reactors
IAEA
No ratings yet
Challenges and Approaches for Selecting, Assessing and Qualifying Commercial Industrial Digital Instrumentation and Control Equipment for Use in Nuclear Power Plant Applications
From Everand
Challenges and Approaches for Selecting, Assessing and Qualifying Commercial Industrial Digital Instrumentation and Control Equipment for Use in Nuclear Power Plant Applications
IAEA
No ratings yet
Summary Review on the Application of Computational Fluid Dynamics in Nuclear Power Plant Design
From Everand
Summary Review on the Application of Computational Fluid Dynamics in Nuclear Power Plant Design
IAEA
No ratings yet
Regulatory Oversight of Ageing Management and Long Term Operation Programme of Nuclear Power Plants
From Everand
Regulatory Oversight of Ageing Management and Long Term Operation Programme of Nuclear Power Plants
IAEA
No ratings yet
Safe Use of Smart Devices in Systems Important to Safety in Nuclear Power Plants
From Everand
Safe Use of Smart Devices in Systems Important to Safety in Nuclear Power Plants
IAEA
No ratings yet
Understanding and Implementing Catch Documentation Schemes: A Guide for National Authorities
From Everand
Understanding and Implementing Catch Documentation Schemes: A Guide for National Authorities
Food and Agriculture Organization of the United Nations
No ratings yet
Guidelines for Engineering Design for Process Safety
From Everand
Guidelines for Engineering Design for Process Safety
CCPS (Center for Chemical Process Safety)
5/5 (2)
Automotive Scan Tool PID Diagnostics
From Everand
Automotive Scan Tool PID Diagnostics
Mandy Concepcion
4.5/5 (5)

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.